literatura knjige lijekovi ili prica o obmani

Literatura knjige dr. Lidije Gajski, Lijekovi ili priča o obmani, str. 1

Literatura knjige dr. Lidije Gajski, Lijekovi ili priča o obmani 1 Istraživanje „Pulsa“: Stavovi građana o reformi zdravstva u Hrvatskoj. Liječničke novine.

15. rujna 2006. 2 Letica S. Teorijski osvrt na Prijedlog nacionalne strategije razvoja zdravstva i “paket“

predloženih zakona o zdravstvenom osiguranju. HČJZ. 2006;7. Dostupno na: http://www.hcjz.hr/clanak.php?id=12916. Pristup 2. studenoga 2006.

3 Čulig J. Kako do racionalne farmakoterapije. HČJZ. 2005;2. Dostupno na: http://www.hcjz.hr/clanak.php?id=12459. Pristup 24. ožujka 2008.

4 Visoko korištenje lijekova pobuđuje i pozornost SZO-a. Liječničke novine. 15. travnja 2004.

5 Zašto je potrebna reforma zdravstva? Liječničke novine. 15. veljače 2006. 6 Ministarstvo zdravstva i socijalne skrbi Republike Hrvatske. Prijedlog nacrta nacionalne

strategije razvitka zdravstva 2006.-2011. Zagreb: Ministarstvo zdravstva i socijalne skrbi; svibanj 2006. Dostupno na: http://vrh.vlada.hr/Download/2006/03/24/1a-149.pdf. Pristup 25. kolovoza 2006.

7 Smith R. Limits to medicine. Medical Nemesis: the expropriation of health. BMJ. 2002;324:923.

8 Null G, Dean C, Feldman M, et al. Death by medicine. Ft. Lauderdale: Life Extension Foundation; 2004. Dostupno na: http://www.lef.org/magazine/mag2004/mar2004_awsi_death_02.htm. Pristup 16. kolovoza 2006.

9 Hamilton W. Big drug´s nicotine war. Sutton: Forces International; 2001. Chapter XI, Big pharmaceuticals, big money. Dostupno na: http://www.forces.org/evidence/pharma/index.htm. Pristup 14. kolovoza 2006.

10 Consumers International. Drugs, doctors and dinners. How drug companies influence health in the developing world. London: Consumers International; 2007. Dostupno na: http://www.consumersinternational.org/shared_asp_files/GFSR.asp?NodeID=97128. Pristup 18. travnja 2008.

11 Freemantle N, Hill S. Medicalisation, limits to medicine, or never enough money to go around? BMJ. 2002;324:864-5.

12 Sveopći napori za racionalizaciju potrošnje lijekova. Liječničke novine. 10. studenoga 2001.

13 Double D. The limits of psychiatry. BMJ. 2002;324:900-4. 14 Summerfield D. Cross cultural perspectives on the medicalisation of human suffering. U:

Rosen GH, editor. Posttraumatic stress disorder: issues and controversies. New York: John Wiley & Sons; 2004. Dostupno na: http://www.instituteofideas.com/transcripts/AllDys_Summerfield_medicaln.pdf. Pristup 5. siječnja 2007.

15 Kendrick M. Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No. BMJ. 2007;334:983.

16 Hersh AL, Stefanick ML, Stafford RS. National use of posmenopausal hormone therapy. JAMA. 2004;291:47-53.

17 Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House; 2004.

18 Fischer MA, Avorn J. Ekonomske posljedice na dokazima utemeljenog propisivanja lijekova u liječenju hipertenzije. JAMA-HR. 2004;4:267-73. Preneseno iz: JAMA. 2004;291:1850-6.


19 Buble T. Mjere za reguliranje troškova za lijekove u Republici Hrvatskoj. U: Udruga poslodavaca u zdravstvu. Lista lijekova Hrvatskog zavoda za zdravstveno osiguranje. Zagreb: Udruga poslodavaca u zdravstvu; studeni 2006.

20 2007. završena sa 755 milijuna kuna dugova za lijekove i bolovanja. Večernji list. 19. ožujka 2008. 21 HZZO 2004. ostvario manjak od 1,170 milijuna kuna. Liječničke novine. 15. ožujka 2005.

22 Lijekovi - gutamo ih sve više. Jutarnji list. 8. ožujka 2008. 23 Bergman Marković B, Kranjčević K, Reiner Ž, et al. Drug therapy of cardiovascular risk

factors: guidelines versus reality in primary health care service. Croat Med J. 2005;46:984-9.

24 Hrvati imaju problema s visokim tlakom i depresijom. Večernji list. 20. prosinca 2004. 25 TASPIC-CRO: Kardiovaskularni rizični čimbenici i njihovo liječenje u bolesnika s

koronarnom bolešću u Hrvatskoj, 1998.-2003. U: Vuletić S, Heim I, Strnad M, et al., ur. Prostorna distribucija populacijskih kardiovaskularnih rizika u Hrvatskoj. Knjiga sažetaka simpozija održanog 2. prosinca 2005. u Zagrebu. Zagreb: Akademija medicinskih znanosti Hrvatske; 2005.

26 Carević V, Božić I, Rakić D, et al. Europska kretanja u sekundarnoj prevenciji infarkta miokarda. Drugi hrvatski internistički kongres. Poster. Liječ Vjesn. 2002;124 Supl 3:42.

27 Hrvatski zavod za zdravstveno osiguranje. Financijski izvještaj Hrvatskog zavoda za zdravstveno osiguranje od siječnja do prosinca 2003. Zagreb: Hrvatski zavod za zdravstveno osiguranje; 2004. Dostupno na: http://www.hzzo-net.hr/informacije/POTROSNJA_LIJEKOVA.pdf. Pristup 22. ožujka 2008.

28 Bencarić L. Registar lijekova u Hrvatskoj. 48. izd. Zagreb: Udruga poslodavaca u zdravstvu; 2005.

29 Udruga poslodavaca u zdravstvu. Lista lijekova Hrvatskog zavoda za zdravstveno osiguranje. Zagreb: Udruga poslodavaca u zdravstvu; siječanj 2008.

30 Liu JLY, Maniadakis N, Gray A, et al. The economic burden of coronary heart disease in the UK. Heart. 2002;88:597-603.

31 AIDS - Propalo 20 godina potrage za cjepivom. Večernji list. 30. ožujka 2008. 32 10 novih lijekova za rak u Hrvatskoj. Globus. 16. lipnja 2006. 33 Plati ili umri - okrutna štednja države na skupim lijekovima. Večernji list. 15. rujna 2005. 34 Bubrežni bolesnici dobivat će nedovoljno ispitani lijek. Večernji list. 16. listopada 2005. 35 Besplatno lijek od šest milijuna kuna. Večernji list. 23. srpnja 2007. 36 Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of

hypertension in the United States. Arch Intern Med. 1995;155:829-37. 37 Fleming TR, DeMets DL. Surrogate end points in clinical trials. Ann Intern Med.

1996;125:605-13. 38 Cranney A, Guyatt G, Griffith L, et al. IX: Summary of meta-analyses of therapies for

postmenopausal osteoporosis. Endocr Rev. 2002;23:570-8. 39 Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. BMJ.

2002;325:269-71. 40 Dukes MNG: Accountability of the pharmaceutical industry. Lancet. 2002;360:1682-4. 41 Veledrogerije „na rubu nesolventnosti“ plaćaju put u Tunis ravnateljima bolnica. Jutarnji

list. 3. veljače 2005. 42 Rat za cjepivo: gripa stiže, cjepivo poskupjelo i kasni. Večernji list. 17. studenoga 2006. 43 European Commission. Health in European Union. Brussels: European Commission; 2007.

Dostupno na: http://ec.europa.eu/health/ph_publication/eb_health.en.pdf. Pristup 29. ožujka 2008.

44 Froom J. Selections from current literature: The cholesterol controversy. Fam Pract.


1989;6:232-7. 45 Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825-

34. 46 Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of

coronary heart disease: safety and absolute benifit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85:265-71.

47 Antonuccio DO, Burns DD, Danton WG. Antidepressants: a triumph of marketing over science? Prevention & Treatment. 2002;5:Article 25. Dostupno na: http://www.antidepressantsfacts.com/2002-07-15-Antonuccio-therapy-vs-med.htm. Pristup 13. listopada 2006.

48 Burgermeister J. Head of German medicines body likens HRT to thalidomide. BMJ. 2003;327:767.

49 Children are dying form ADHD drugs. National Alliance against Mandated Mental Health Screening and Psychiatric Drugging od Children. Dostupno na: http://www.ritalindeath.com/. Pristup 31. ožujka 2008.

50 Healy D. Lines of evidence on the risks of suicide with selective serononin reuptake inhibitors. Psychother Psychosom. 2003;72:71-9.

51 Fergusson D, Doucette S, Cranley Glass K, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330:396-9.

52 Weinstein RA. Nosocomial infection update. Emerg Infect Dis. 1998;4:416-20. 53 Lazarou J, Pomerantz BH, Corey PN. Incidence of adverse drug reactions in hospitalized

patients. A meta-analysis of prospective studies. JAMA. 1998;279:1200-5. 54 Starfield B. Is US health really the best in the world? JAMA. 2000;284:483-5. 55 195,000 U.S. deaths blamed on hospital errors. MSNBC News; 2004 Jul 28. Dostupno na:

http://www.msnbc.msn.com/id/5536730/. Pristup 5. listopada 2006. 56 Moynihan R. The marketing of a disease: female sexual dysfunction. BMJ. 2005;330:192-

4. 57 American Association of Clinical Endocrinologists (AACE). Medical guidelines for

clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9:545-64.

58 Gale EAM. Lessons from the glitazones: a story of drug development. Lancet. 2001;357:1870-5.

59 Nissen SE, Wolsky K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71.

60 Sin DD, Man J, Sharpe H, et al. Farmakološko zbrinjavanje za kontrolu egzacerbacija astme u odraslih. JAMA-HR. 2004;6:463-70. Preneseno iz: JAMA. 2004;292:367-76.

61 Dachverband Osteologie (DVO). Osteoporosis in postmenopausal women. DVO Guideline. Essen: Lutherhaus; 2003. Dostupno na: http://www.lutherhaus.de/osteo/leitlinien-dvo/english/osteoporosis-in-postmenopausal-women.pdf. Pristup 12. veljače 2005.

62 Odvina CV, Zerwekh JE, Sudhaker R, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-301.

63 American Dental Association. Osteonecrosis of the jaw. Chicago: American Dental Association; 2006. Dostupno na: http://www.ada.org/prof/resources/topics/osteonecrosis.asp. Pristup 6. prosinca 2006.

64 Jošt M, Šooš E. Lice i naličje cijepljenja protiv hepatitisa B. Nova prisutnost. 2007;5:305-24.

65 Heerdink ER, Urquhart J, Leufkens HG. Changes in prescribed drug doses after market


introduction. Pharmacoepidemiol Drug Saf. 2002;11:447-53. 66 Ravnskov U, Rosch PJ, Sutter MC, et al. Should we lower cholesterol as much as

possible? BMJ. 2006;332:1330-2. 67 Napoli M. Cholesterol skeptics and the bad news about statin drugs. New York: Center for

Medical Consumers; 2003. Dostupno na: http://www.medicalconsumers.org/pages/ CHOLESTEROLSKEPTICSCONFERENCEREPORT.html. Pristup 31. ožujka 2008.

68 Wagstaff LR, Mitton MW, McLendon Arvik B, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871-80.

69 Newman CB, Palmer G, Silbershatz H, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003;92:670-6.

70 Brown MJ, Brown J. Does angiotensin-II protect against strokes? Lancet. 1986;2:427-9. 71 Fournier A, Oprisiu R, Mazouz H, et al. Stroke death rate annual decrease reversal and

prescription decrease of antihypertensive drugs stimulating the angiotensin II formation (abstract). Am J Hypertens. 2002;15:106A.

72 Jošt M, Cox TS. Intelektualni izazov tehnologije samouništenja/Intellectual challenge of self- destruction technology. Križevci: Matica hrvatska Križevci; 2003.

73 Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-9.

74 Topol EJ. Lijekovi za liječenje artritisa i srčanožilna zbivanja - „Kuća od koksibovih karata“. JAMA-HR. 2005;3:236-8. Preneseno iz: JAMA. 2005:293:366-8.

75 Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996;275:55-60.

76 Napoli M. C-reactive protein testing not for everyone. New York: Center for Medical Consumers; 2005. Dostupno na: http://www.medicalconsumers.org/pages/C-ReactiveProteinTestingNotforEveryone.html. Pristup 31. ožujka 2008.

77 Kako smanjiti visoku potrošnju lijekova u Hrvatskoj? Farmaceutski glasnik. 2004;60:98-106.

78 Leape LL. Error in medicine. JAMA. 1994;272:1851-7. 79 International Federation of Pharmaceutical Manufacturers and Associations. IFPMA Code

of Pharmaceutical Marketing Practices. Geneva: International Federation of Pharmaceutical Manufacturers and Associations; 1994. Dostupno na: http://www.ifpma.org/News/news_market.aspx. Pristup 23. kolovoza 2006.

80 McKeown T. The role of medicine: dream, mirage, or nemesis? London: Nuffield Provincial Hospitals Trust; 1976.

81 Treća zajednička radna skupina za prevenciju kardiovaskularnih bolesti u kliničkoj praksi Europskoga kardiološkog društva i ostalih društava. Europske smjernice za prevenciju bolesti srca i krvnih žila u kliničkoj praksi (2003.). Zagreb: Hrvatsko kardiološko društvo; Hrvatski zavod za javno zdravstvo; Hrvatsko društvo za aterosklerozu; Hrvatsko internističko društvo; Hrvatsko društvo za arterijsku hipertenziju; Hrvatsko društvo za debljinu; Hrvatska udružba obiteljske medicine; 2004.

82 Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. Circulation. 2000;102:3137-47.

83 Hrvatski zavod za javno zdravstvo. Hrvatski zdravstvenostatistički ljetopis za 2006. godinu. Zagreb: Hrvatski zavod za javno zdravstvo; 2007.

84 Kralj V, Hrabak-Žerjavić V. Javnozdravstveni značaj kardiovaskularnih bolesti. Kardio list. 2008;3:74.


85 Moss RW. Newsletter # 127. Cancer Healing; 2004 Apr. Dostupno na: http://www.cancer_healing.com/cancer_moss_reports.php. Pristup 3. travnja 2008.

86 Mercola J. The man who questions chemotherapy: dr. Ralph Moss. Mercola; 2008. Dostupno na: http://www.mercola.com/article/cancer/cancer_options.htm. Pristup 3. travnja 2008.

87 Healy D. The dilemmas posed by new and fashionable treatments. Adv Psychiatr Treat. 2001;7:322-7.

88 Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 2000;355:675-87.

89 Task force on arteriosclerosis. Excerpt from Thomas J. Moore's book “Heart failure“ as it appeared in The Atlantic Monthly. Atlantic; 1989 Sep. Dostupno na: http://www.oralchelation.net/heartdisease/ChapterFive/page5g.htm. Pristup 18. siječnja 2007.

90 Napoli M. How we came to believe that the low-fat diet is good and cholesterol is bad. New York: Center for Medical Consumers; 2003. Dostupno na: http://www.medicalconsumers.org/pages/how_we_came_to_believe.html. Pristup 26. listopada 2006.

91 Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45.

92 Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-9.

93 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.

94 Rath M. Making health a human right. Berlin: Dr. Rath Health Foundation; 1999. Dostupno na: http://www4.dr-rath-foundation.org/ PHARMACEUTICAL_ BUSINESS/liberation_ of_human_ health/liberation06.htm. Pristup 12. listopada 2006.

95 The documentation about „Codex Alimentarius“. Berlin: Dr. Rath Health Foundation. Dostupno na: http://www4.dr-rath-foundation. org/ PHARMACEUTICAL_BUSINESS/ health_movement_against_codex/health_movement05.htm. Pristup 12. listopada 2006.

96 Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-39.

97 Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-98.

98 Gueyffier F, Boutitie F, Boissel J, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data in randomised, controlled trials. Ann Intern Med. 1997;126:761-7.

99 Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. A network meta-analysis. JAMA. 2003;289:2534-44.

100 Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly. Meta-analysis of outcome trials. Lancet. 2000;355:865-72.

101 Elliott W. Cardiovascular events in clinical trials of antihypertensive drugs vs. placebo/no treatment. A meta-analysis. J Hypertens 2005;23 Suppl 2:S273. Abstact 9B.2.

102 Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure


lowering and low- dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-62.

103 Mulrow CD, Cornell JA, Herrera CR, et al. Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA. 1994;272:1932-8.

104 Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens. 1996;10:1-8.

105 Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med. 1999;159:2004-9.

106 Gueyffier F, Bullpit C, Boissel J, et al. Antihypertensive drugs in very old people. A subgroup meta- analysis of randomised controlled trials. Lancet. 1999;353:793-6.

107 Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and micorvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-9.

108 Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35:539-43.

109 Sackett DL, Cook RJ. Understanding clinical trials. BMJ. 1994;309:755-6. 110 BMJ rapid responses to: Westin S, Heath I. Tresholds for normal blood pressure and

serum cholesterol. BMJ. 2005;330:1461-2. Dostupno na: http://bmj.bmjjournals.com/cgi/eletters/330/7506/1461. Pristup 25. kolovoza 2006.

111 Europsko društvo za hipertenziju - Europsko kardiološko društvo, Odbor za smjernice. Smjernice za dijagnosticiranje i liječenje arterijske hipertenzije. 2003. Zagreb: Hrvatsko kardiološko društvo; 2004.

112 Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739-45.

113 Blood Pressure Lowering Treatment Trialists´ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-64.

114 Blood Pressure Lowering Treatment Trialists´ Collaboration. Effects of different blood-pressure- lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.

115 Staessen JA, Wang J, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-76.

116 Elliott W. Meta-analysis of cardiovascular events during long-term antihypertensive treatment with an initial diuretic or beta-blocker vs. ace-inhibitor vs. calcium antagonist. J Hypertens. 2005;23 Suppl 2:S373. Abstract P3.346.

117 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.

118 Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.

119 Davies BR, Furberg CD, Wright JT, et al. ALLHAT: setting the record straight. Ann


Intern Med. 2004;141:39-46. 120 Združeni nacionalni odbor za sprječavanje, otkrivanje, procjenu i liječenje visokog

krvnog tlaka. Sedmo izvješće Združenog nacionalnog odbora za sprječavanje, otkrivanje, procjenu i liječenje visokog krvnog tlaka. Izvješće JNC 7. JAMA-HR. 2003;5:367-80. Preneseno iz: JAMA. 2003;289:2560-72.

121 Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens. 2002;20:2099-110.

122 Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ann Intern Med. 2001;135:73-87.

123 Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.

124 Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.

125 Amarenco P, Tonkin AM. Statins for stroke prevention. Circulation. 2004;109 Suppl I:III-44-9.

126 Trubelja N, Vaughan C, Coplan NL. The role of statins in preventing stroke. Prev Cardiol. 2005;8:98-101.

127 Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-30.

128 Jackson PR, Wallis EJ, Haq IU, et al. Statins for primary prevention: at what coronary risk is safety assured? Br J Clin Pharmacol. 2001;52:439-46.

129 LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-6.

130 Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.

131 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.

132 Therapeutics Initiative. Statin's benefit for secondary prevention confirmed. Vancouver: University of British Columbia; 2003. Dostupno na: http://www.ti.ubc.ca/PDF/49.pdf. Pristup 27. listopada 2006.

133 Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ. 2000;321:983-6.

134 Therapeutics Initiative. Do statins have a role in primary prevention? Vancouver: University of British Columbia; 2003. Dostupno na: http://www.ti.ubc.ca/PDF/48.pdf. Pristup 24. rujna 2007.

135 Abramson J, Wright JM. Are lipid-lowering guidelines evidence-based? Lancet. 2007;369:168-9.

136 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-7.

137 Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-22.


138 Sever PS, Dahlöf B, Poulter NL, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.

139 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.

140 Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.

141 Walsh JME, Pignone M. Farmakološko liječenje hiperlipidemije u žena. JAMA-HR. 2004;4:311-21. Preneseno iz: JAMA. 2004;291:2243-52.

142 Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-30.

143 LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35.

144 Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96:4211-8.

145 The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003;24:28-66.

146 Schwartz GG, Olsson AG, Ezekowitz MD, et al. Učinci atorvastatina na ranu pojavu recidiva ishemijskih događaja u akutnim koronarnim sindromima. Studija MIRACL: randomizirano kontrolirano ispitivanje. JAMA-HR. 2001;3:167-74. Preneseno iz: JAMA. 2001;285:1711-8.

147 Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.

148 Pedersen TR, Faergeman O, Kastelein JJP, et al. Učinkovitost visoke doze atorvastatina u odnosu na uobičajenu dozu simvastatina u sekundarnoj prevenciji provođenoj nakon infarkta miokarda. Studija IDEAL: kontrolirana studija slučajnog odabira. JAMA-HR. 2006;2:89-98. Preneseno iz: JAMA. 2005;294:2437-45.

149 De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z Trial. JAMA. 2004;292:1307-16.

150 Bloomfield Rubins H, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-8.

151 Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit. Circulation. 1995;91:2274-82.

152 Hooper L, Thompson RL, Harrison RA, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database of Systematic Reviews; 2004 Oct. Dostupno na: http://www.cochrane.org/reviews/en/ab003177.html. Pristup 5. travnja 2008.

153 Therapeutics Initiative. A systematic review of ezetimibe for the treatment of adult patients with hypercholesterolemia. Vancouver: University of British Columbia; 2008. Dostupno na: http://www.ti.ubc.ca/en/node/185. Pristup 5. travnja 2008.


154 Herbert P, Hennekens CH. Pregled četiriju randomiziranih kliničkih pokusa primjene terapije aspirinom u primarnoj prevenciji vaskularne bolesti. JAMA-HR. 2001;2:115-9. Preneseno iz: Arch Intern Med. 2000;160:3123-7.

155 Jochmann N, Stangl K, Garbe E, et al. Female specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J. 2005;26:1585-95.

156 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.

157 Finne P, Reunanen A, Stenman S, et al. Pojavnost završnog stupnja bubrežne bolesti u bolesnika koji boluju od šećerne bolesti tipa 1. JAMA-HR. 2006;1:29-35. Preneseno iz: JAMA. 2005;294:1782-7.

158 Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-81.

159 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.

160 Nathan DM. Some answers, more controversy from UKPDS. Lancet. 1998;352:832-3. 161 The Diabetes Control and Complications Trial Research Group. The effect of intensive

treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.

162 Reichard P, Berglund B, Britz A, et al. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): The Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med. 1991;230:101-8.

163 Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17.

164 Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF, et al. The response of diabetic retinopathy to 41 months of multiple insulin injections, insulin pumps, and conventional insulin therapy. Arch Ophtalmol. 1988;106:1242-6.

165 Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Intern Med. 1997;157:181-8.

166 Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-9.

167 Grupa za objavljivanje istraživačke skupine DCCT/EDIC. Održani učinak pojačane terapije šećerne bolesti tipa 1 na razvoj i progresiju dijabetičke nefropatije. Epidemiološka studija o liječenju i komplikacijama šećerne bolesti (studija EDIC). JAMA-HR. 2004;1:35-43. Preneseno iz: JAMA. 2003;290:2159-67.

168 Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med. 2001;111:633-42.

169 Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53.

170 Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA. 2003;290:486-94.

171 American Diabetes Association; European Association for the Study of Diabetes.


Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963-72.

172 Klimt CR, Knatterud GL, Meinert CL, et al. A study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19 Suppl 2:747-830.

173 Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167-72.

174 James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet. 2000;356:2119-25.

175 Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160-7.

176 Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-13.

177 Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6,8 years of hormone therapy. Heart and estrogen/progestin replacement study folow-up (HERS II). JAMA. 2002;288:49-57.

178 Writing Group for the Women´s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women´s Health Initiative randomized controlled trial. JAMA. 2002;288:321-33.

179 Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy. Scientific review. JAMA. 2002;288:872-81.

180 Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women´s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-62.

181 Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670-4.

182 Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporosis Int. 2000;11:556-61.

183 Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women. A prospective study. Arch Intern Med. 1999;159:1215-20.

184 Cranney A, Wells G, Willon A, et al. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:508-16.

185 Napoli M. Bone density testing: new recommendations for when to start. New York: Center for Medical Consumers; 2003. Dostupno na: http://www.medicalconsumers.org/pages/bone_density_testing.html. Pristup 12. svibnja 2007.

186 Khan A, Warner HA, Brown WA, et al. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. An analysis of the Food and Drug Administration Database. Arch Gen Psychiatry. 2000;57:311-7.

187 Khan A, Khan S, Kolts R, et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160:790-2.

188 Storosum JG, Van Zwieten BJ, Van den Brink W, et al. Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry. 2001;158:1271-5.

189 Gunnell D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. BMJ. 2004;329:34-8.

190 Kirsch I, Moore TJ, Scoboria A, et al. The Emperor´s new drugs: an analysis of


antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment. 2002;5:Article 23. Dostupno na: http://journals.apa.org/prevention/volume5/pre0050023a.html. Pristup 14. veljače 2007.

191 Kirsch I, Scoboria A, Moore TJ. Antidepressants and placebos: secrets, revelations, and unanswered questions. Prevention & Treatment. 2002;5:Article 33. Dostupno na: http://journals.apa.org/prevention/volume5/pre0050033r.html. Pristup 20. prosinca 2006.

192 Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta- analysis of data submitted to the Food and Drug Administration. PloS Med. 2008;5(2):e45. Dostupno na: http://medicine.plosjournals.org/perlserv/?request=getdocument&doi=10.1371%2Fjournal.pmed.0050045. Pristup 31. ožujka 2008.

193 National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: National Institute for Clinical Excellence; 2004. Dostupno na: http://www.nice.org.uk/pdf/CG023quickrefguide.pdf. Pristup 6. rujna 2006.

194 Geddes JR, Cipriani A. Selective serotonin reuptake inhibitors. BMJ. 2004;329:809-10. 195 Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression.

Cochrane Database of Systematic Reviews; 2001 Apr (updated 2003 Oct). Dostupno na: http://www.cochrane.org/reviews/en/ab003012.html. Pristup 2. ožujka 2007.

196 American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry. 2000;157 Suppl 4:1-45.

197 Snow V, Lascher S, Mottur-Pilson C, for the American College of Physicians - American Society of Internal Medicine. Pharmacologic treatment of acute major depression and dysthymia. Clinical guideline, part 1. Ann Intern Med. 2000;132:738-42.

198 Geddes JR, Freemantle N, Mason J, et al. Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Database of Systematic Reviews; 2006. Dostupno na: http://www.ncbi.nlm.nih.gov/pubmed/10796826. Pristup 4. travnja 2007.

199 Lett H, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms and treatment. Psychosom Med. 2004;66:305-15.

200 Writing Commitee for the ENRICHD Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction. JAMA. 2003;289:3106-16.

201 Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol. 2001;52:179-84.

202 Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medication: association with use of tricyclic agents. Am J Med. 2000;108:2-8.

203 Abel U. Chemotherapy of advanced epithelial cancer - a critical review. Biomed Pharmacother. 1992;46:439-52.

204 Moss RW. Questioning chemotherapy. New York: Equinox Press; 1995. 205 Gottlieb S. Chemotherapy may be overused at the end of life. BMJ. 2001;322:1267. 206 Sin DD, McAlister FA, Man SFP, et al. Suvremeno zbrinjavanje kronične opstruktivne

plućne bolesti. JAMA-HR. 2004;1:61-70. Preneseno iz: JAMA. 2003;290:2301-12. 207 Levine B. Eli Lilly, Zyprexa, & the Bush family. The diseasing of our malaise. Z

Magazine Online. 2004 May. Dostupno na: http://zmagsite.zmag.org/May2004/levine0504.html. Pristup 3.

studenoga 2006.


208 Piccirillo JF, Mager DE, Frisse ME, et al. Značajnost antibiotika prvog izbora u odnosu na antibiotike drugog izbora za liječenje aktunog nekompliciranog sinuitisa. JAMA-HR. 2002;1:33-40. Preneseno iz: JAMA. 2001;286:1845-56.

209 McIsaac WJ, Kellner JD, Aufricht P, et al. Iskustveno vrednovanje smjernica za zbrinjavanje faringitisa u djece i odraslih. JAMA-HR. 2004;4:275-84. Preneseno iz: JAMA. 2004;291:1587-95.

210 Flamm SL. Kronična infekcija virusom hepatitisa C. JAMA-HR. 2003;5:383-7. Preneseno iz: JAMA. 2003;289:2413-7.

211 Novi lijekovi za liječenje HIV-a. JAMA-HR. 2002;3:239-40. 212 Only safe vaccine is one that is never used. Vaccination quotes from doctors and

scientists. Rense; 2001. Dostupno na: http://www.rense.com/general7/onlysafe.htm. Pristup 16. veljače 2008.

213 Stav Američkog udruženja pedijatara o cjepivu protiv HPV-a. Zagreb: PLIVAzdravlje; 3. travnja 2007. Dostupno na: http://www.plivazdravlje.ba/?section=home&cat=w&id=16254&show=1. Pristup 7. veljače 2008.

214 Ilič I. Medicinska Nemezis. Beograd: Vuk Karadžić; 1975. 215 EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery

disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-8.

216 The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-68.

217 Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ. 2003;327:1264-7.

218 Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-24.

219 Alderman MH. Povratak na INVEST. JAMA-HR. 2004;2:161-3. Preneseno iz: JAMA. 2003;290:2859-62.

220 Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. N Engl J Med. 2000;342:1539-44.

221 Kidwell CS, Liebeskind DS, Starkman S, et al. Trends in acute ischemic stroke trials through the 20th century. Stroke. 2001;32:1349-59.

222 Marušić M. i sur. Uvod u znanstveni rad u medicini. 3. izd. Zagreb: Medicinska naklada; 2004.

223 Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-12.

224 Chalmers TC, Celano P, Sacks HS, et al. Bias in treatment assignment in contolled clinical trials. N Engl J Med. 1983;309:1358-61.

225 Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ. 2001;323:42-6.

226 Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609-13.

227 Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomised controlled trials. The CONSORT statement. JAMA. 1996;276:637-9.

228 Moher D, Schulz KF, Altman DG. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001;134:657-62.


229 Hotopf M, Lewis G, Normand C. Putting trials on trial - the costs and consequences of small trials in depression: a systematic review of methodology. J Epidemiol Community Health. 1997;51:354-8.

230 Hewitt C, Hahn S, Torgerson DJ, et al. Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals. BMJ. 2005;330:1057-8.

231 Saunders P. Actonel: drug company keeps data from collaborating scientists. London: Institute of Science in Society; 2006 May. Dostupno na: http://www.i-sis.org.uk/actonel.php. Pristup 16. kolovoza 2006.

232 Liječnik izmislio istraživanje o raku! Večernji list. 17. siječnja 2006. 233 Brownlee S. Why you can´t trust medical journals anymore. Washington Monthly. 2004

Apr. Dostupno na: http://www.washingtonmonthly.com/features/2004/0404.brownlee.html. Pristup 6. prosinca 2006.

234 Chiasson JL, Josse R, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP- NIDDM randomised trial. Lancet. 2002,359:2072-7.

235 Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol. 2002;39:1567-73.

236 Mitka M. Eksperti raspravljaju o proširenju uporabe opioida u liječenju kronične boli koja nije prouzročena zloćudnim procesom. JAMA-HR. 2003;6:437-9. Preneseno iz: JAMA. 2003;289:2347-8.

237 Rochon PA. The evaluation of clinical trials: inclusion and representation. CMAJ. 1998;159:1373-4.

238 Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061-7.

239 Buxton Bridges C, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults. JAMA. 2000;284:1655-63.

240 Sprague Zones J. What is the price of hope? San Francisco: Breast Cancer Action; 1995. Dostupno na: http://www.bcaction.org/Pages/SearchablePages/1995Newsletters/Newsletter033A.html. Pristup 30. listopada 2006.

241 Steiner M, Steinberg S, Stewart D, et al. Fluoxetin in the treatment of premenstrual dysphoria. N Engl J Med. 1995;332:1529-34.

242 Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertaline treatment: a randomized controlled trial. JAMA. 1997;278:983-8.

243 Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. Strategija zbrinjavanja hipertenzije primjenom antagonista kalcija u odnosu na strategiju zbrinjavanja lijekovima koji ne ostvaruju takvo djelovanje u oboljelih od koronarne bolesti. Studija INVEST: kontrolirana studija slučajnog odabira. JAMA-HR. 2004;2:113-29. Preneseno iz: JAMA. 2003;290:2805-16.

244 The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52-61.

245 Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17.


246 Lewis SC, Warlow CP. How to spot bias and other potential problems in randomised controlled trials. J Neurol Neurosurg Psychiatry. 2004;75:181-7.

247 Rabkin JG, Markovitz JS, Stewart J, et al. How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Research. 1986;19:75-86.

248 Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999;282:1752-9.

249 Bray GA. Obesity, a time bomb to be defused. Lancet. 1998;352:160-1. 250 Rochon PA, Gurwitz JH, Simms RW, et el. A study of manufacturer-supported trials of

nonsteroidal anti-infammatory drugs in the treatment of arthritis. Arch Intern Med. 1994;154:157-63.

251 Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167-70.

252 Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens. 2003;21:875-86.

253 Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-6.

254 Buch P, Rasmussen S, Abildstrom SZ, et al. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur Heart J. 2005;26:145-62.

255 Jüni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 2002;324:1287-8.

256 Mueller PS, Montori VM, Bassler D, et al. Ethical issues in stopping randomized trials early because of apparent benefit. Ann Intern Med. 2007;146:878-81.

257 Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577-81.

258 Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422-7.

259 Zanchetti A, Crepaldi G, Bond G, et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke. 2004;35:2807-12.

260 Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-40.

261 Kinlay S, Selwyn AP, Delagrange D, et al. Biological mechanisms for the clinical success of lipid- lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol. 1996;7:389-97.

262 Staal KP, Roos JC, Manoliu RA, et al. Variations in diagnostic performances of dual-energy X-ray absorptiometry in the northwest of The Netherlands. Osteoporosis Int. 2004;15:335-44.

263 Rogić D. Biokemijski biljezi koronarne bolesti. JAMA-HR. 2005;2:157-8.


264 BMJ rapid responses to: Khaw K-T, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322:15-8. Dostupno na: http://www.bmj.com/cgi/eletters/322/7277/15. Pristup 3. studenoga 2006.

265 Nissen SE, Tuzcu EM, Libby P, et al. Učinci antihipertenzivnih lijekova na srčanožilna zbivanja u bolesnika s koronarnom bolešću i normalnim krvnim tlakom. Studija CAMELOT: kontrolirani pokus slučajnog odabira. JAMA-HR. 2005;1:29-38. Preneseno iz: JAMA. 2004;292:2217-26.

266 Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA. 1999;282:790-5.

267 Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA. 1999;282:786-90.

268 De Fine Olivarius N, Andreasen AH. Some answers, more controversy from UKPDS. Lancet. 1998;352:832-3.

269 Steinhubl SR, Berger PB, Man III JT, et al. Rana i održana dvojna terapija peroralnim antitromobocitnim lijekovima nakon perkutanog koronarnog zahvata. JAMA-HR. 2003;2:113-23. Preneseno iz: JAMA. 2002;288:2411-20.

270 Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.

271 Lenzer J. Pfizer criticised over delay in admitting drug's problems. BMJ. 2004;329:935. 272 Fukurawa TA. All clinical trials must be reported in detail and made publicly available.

BMJ. 2004;329:626. 273 PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood

pressure-lowering regimen among 6 108 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41.

274 Wennberg R, Zimmermann R. The PROGRESS trial three years later: time for a balanced report of effectiveness. BMJ. 2004;329:968-70.

275 Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA. 2000;284:1247-55.

276 Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomized drug trials. JAMA. 2003;290:921-8.

277 Chan A-W, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials. JAMA. 2004;291:2457-65.

278 Liječenje agresivnih non-Hodgkin limfoma. Liječničke novine. 15. prosinca 2004. 279 Menotti A, Blackburn H, Kromhout D, et al. Changes in population cholesterol levels and

coronary heart disease deaths in seven countries. Eur Heart J. 1997;18:566-71. 280 Balkau B, Shipley H, Jarret RJ, et al. High blood glucose concentration is a risk factor for

mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360-7.

281 Rockwood K, Kirkland S, Hogan DB, et al. Use od lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-7.

282 MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-74.


283 Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.

284 Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.

285 Reumatoidni artritis i osteoartritis. Liječničke novine. 15. studenoga 2004. 286 Cifu A, Levinson W. Gripa. JAMA-HR. 2001;2:133-5. Preneseno iz: JAMA.

2000;284:2847-9. 287 Moynihan R. The making of a disease: female sexual dysfunction. BMJ. 2003;326:45-7. 288 Moynihan R, Heath I, Henry D, et al. Selling sickness: the pharmaceutical industry and

disease mongering. BMJ. 2002;324:886-91. 289 Mark DH. Smrti pripisane debljini. JAMA-HR. 2005;4:320-1. Preneseno iz: JAMA.

2005;293:1918-9. 290 International Lipid Information Bureau (ILIB). Dyslipidemia and coronary heart disease.

3rd ed. New York: International Lipid Information Bureau; 2003. 291 Moser M. The cost of treating hypertension: can we keep it under control without

compromising the level of care? Am J Hypertens. 1998;11:120S-27S. 292 Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against

influenza in healthy, working adults. N Engl J Med. 1995;333:889-93. 293 Moja LP, Telare E, D'Amico R, et al. Assessment of methodological quality of primary

studies by systematic reviews: results of the metaquality cross sectional study. BMJ. 2005;330:1053-7.

294 Naylor CD. Meta-analysis and the meta-epidemiology of clinical research. BMJ. 1997;315:617-9.

295 Easterbrook PJ, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet. 1991;337:867-72.

296 Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003;326:1171-3.

297 Bardy AH. Bias in reporting clinical trials. Br J Clin Pharmacol. 1998;46:147-50. 298 Sukob interesa u medicini. Liječničke novine. 15. svibnja 2002. 299 Rennie D. Fair conduct and fair reporting of clinical trials. JAMA. 1999;282:1766-8. 300 Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in

childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363:1341-5.

301 Dyer O. GlaxoSmithKline to set up comprehensive online clinical trials register. BMJ. 2004;329:590.

302 Bad medicine. Guardian. 2004 Jun 12. Dostupno na: http://www.guardian.co.uk/leaders/story/0,,1237013,00.html. Pristup 29. studenoga 2006.

303 Gøtzsche PC. Multiple publication of reports of drug trials. Eur J Clin Pharmacol. 1989;36:429-32.

304 Tramer MR, Reynolds DJM, Moore RA, et al. Impact of covert duplicate publication on meta- analysis: a case study. BMJ. 1997;315:635-40.

305 BMJ rapid responses to: Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-24. Dostupno na: http://bmj.bmjjournals.com/cgi/eletters/326/7404/1419. Pristup 1. rujna 2006.

306 The Evidence Based Medicine Working Group. Users´ guides to medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? JAMA.


1995;274:570-4. 307 The Evidence Based Medicine Working Group. Users´ guides to medical literature. VIII.

How to use clinical practice guidelines. B. What are the recommendations and will they help you in caring for your patients? JAMA. 1995;274:1630-2.

308 Haycox A, Bagust A, Walley T. Clinical guidelines - the hidden costs. BMJ. 1999;318:391-3.

309 Cluzeau FA, Littlejohns P, Grimshaw JM, et al. Development and application of a generic methodology to assess the quality of clinical guidelines. Int J Qual Health Care. 1999;11:21-8.

310 Grilli R, Magrini N, Penn A, et al. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000;355:103-6.

311 Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA. 1999;281:1900-5.

312 Graham ID, Beardall S, Carter AO, et al. What is the quality of drug therapy clinical practice guidelines in Canada? CMAJ. 2001;165:157-63.

313 Stiegler M, Rummel C, Wahlbeck K, et al. European psychiatric treatment guidelines: is the glass half full or half empty? Eur Psychiatry. 2005;20:554-8.

314 Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J. 1998;19:1434-503.

315 BMJ rapid responses to: Williams B, Poulter NR, Brown HJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). BMJ. 2004;328:634-40. Dostupno na: http://bmj.bmjjournals.com/cgi/eletters/328/7440/634. Pristup 7. kolovoza 2007.

316 Williams B, Poulter NR, Brown HJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004;328:634-40.

317 European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut. 1997;41:8-13.

318 Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-80.

319 Europsko kardiološko društvo. Smjernice za dijagnosticiranje i liječenje kroničnog zatajivanja srca. (2001.). Zagreb: Hrvatsko kardiološko društvo.

320 Cranney A, Waldegger L, Graham ID, et al. Systematic assessment of the quality of osteoporosis guidelines. BMC Musculoskelet Disord. 2002;3:20.

321 Priori SG. Medical practice guidelines. Separating science from economics. Eur Heart J. 2003;24:1962-4.

322 Hrvatsko društvo za nefrologiju, dijalizu i transplantaciju Hrvatskog liječničkog zbora. Liječenje anemije u bolesnika s kroničnim zatajenjem bubrega. Zagreb: Ministarstvo zdravstva i socijalne skrbi Republike Hrvatske; 2003. Dostupno na: http://www.tel.hr/mzrh/Klinicke_Smjernice/anemija.htm. Pristup 27. rujna 2006.

323 Warburton RN. What do we gain from the sixth conary heart disease drug? BMJ. 2003;327:1237-8.

324 Van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors: whom to treat? Eur Heart J. 2001;22:751-61.

325 Jenkins AJ. Might money spent on statins be better spent? BMJ. 2003;327:933. 326 Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice?

Lancet. 2004;364:1684-9.


327 Chan KBJ, Man-Son-Hing J, Molnar FJ, et al. How well is the clinical importance of study results reported? An assessment of randomized controlled trials. CMAJ. 2001;165:1197-202.

328 Lang T. Twenty statistical errors even YOU can find in biomedical research articles. Croat Med J. 2004;45:361-70.

329 Cummings SR, Black DM, Thompson DE, et al. Effect of alendronat on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82.

330 Forrow L, Taylor WC, Arnold RM. Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med. 1992;92:121-4.

331 Bucher HC, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ. 1994;309:761-4.

332 Lewis DK, Barton S. Who decides when to start preventive treatment? A questionnaire survey to compare the views of different population subgroups. J Epidemiol Community Health. 2003;57:241-2.

333 Malenka DJ, Baron JA, Johansen S, et al. The framing effect of relative and absolute risk. J Gen Intern Med. 1993;8:543-8.

334 Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making. 1995;15:152-7.

335 Fahey T, Griffiths S, Peters TJ. Evidence based purchasing: understanding results of clinical trials and systematic reviews. BMJ. 1995;311:1056-9.

336 Kjeldsen SE, Dahlöf B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint Reduction (LIFE) Substudy. JAMA. 2002;288:1491-8.

337 Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials. 1989;10:31-56.

338 Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000;132:743-56.

339 The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-105.

340 Hrvatski registar nadomještanja bubrežne funkcije. Treći hrvatski internistički kongres. Poster. Liječ Vjesn. 2004;126 Supl 3:13.

341 Jones P, Kafonek S, Laurora I, et al. Comparative efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-7.

342 Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.

343 Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-65.

344 Khaw K-T, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition


(EPIC-Norfolk). BMJ. 2001;322:15-8. 345 Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk

of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-8.

346 Napoli M. (Almost) Everything you need to know about statin drugs. New York: Center for Medical Consumers; 2003. Dostupno na: http://www.medicalconsumers.org/pages/AlmostEverythingYouNeedtoKnowAboutStatinDrugs.html. Pristup 29. kolovoza 2006.

347 Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.

348 Skolbekken J-A. The risk epidemic in medical journals. Soc Sci Med. 1995;40:291-305. 349 Franklin SS, Wong ND. Cardiovascular risk evaluation: an inexact science. J Hypertens.

2002;20:2127-30. 350 Taylor RS, Drummond MF, Salkeld G, et al. Inclusion of cost effectiveness in licensing

requirements of new drugs: the fourth hurdle. BMJ. 2004;329:972-5. 351 Johannesson M, Jönsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment

to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332-6.

352 Caro J, Klittich W, McGuire A, et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. Eur Heart J. 1999;20:263-8.

353 Johannesson M, Dahlöf B, Lindholm LH, et al. The cost-effectiveness of treating hypertension in elderly people - an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Intern Med. 1993;234:317-23.

354 Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics. 1995;7:242-50.

355 National Institutes of Health. Excerpts from the United States Renal Data System´s 2000 annual data report: atlas of end-stage renal disease in the United States: economic costs of ESRD. Am J Kidney Dis. 2000;36 Suppl 2:S163-76.

356 Dijabetesom uzrokovana bolest bubrega i srca. U: Simpozij „Bubreg i srce“. Zbornik radova simpozija održanog 14. ožujka 2003. u Zagrebu. Zagreb: Akademija medicinskih znanosti Hrvatske; Hrvatsko društvo za nefrologiju, dijalizu i transplantaciju Hrvatskog liječničkog zbora; 2003.

357 U Hrvatskoj više od 150 tisuća astmatičara i loša kontrola bolesti. Liječničke novine. 15. svibnja 2003.

358 Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-26. 359 Hackam D, Anand S. Novootkriveni čimbenici rizika za razvoj aterosklerotske bolesti.

Kritički pregled dokaza. JAMA-HR. 2003;6:463-71. Preneseno iz: JAMA. 2003;290:932-40.

360 Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.

361 Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.

362 Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001;88:672-4.


363 Baroldi G, Bigi R, Cortigiani L. Ultrasound imaging versus morphopathology in cardiovascular diseases. Coronary atherosclerotic plaque. Cardiovasc Ultrasound. 2004;2:29.

364 Rath M. The Stanford speech: Eradicating heart disease. Berlin: Dr. Rath Health Foundation; 2002. Dostupno na: http://www4.dr-rath-foundation.org/NHC/cardiovascular_disease/lecture/standford_speech.htm. Pristup 21. travnja 2008.

365 Mitka M. Istraživanja aortalne stenoze. Aktivan, možda izlječiv proces? JAMA-HR. 2004;1:11-2. Preneseno iz: JAMA. 2003;289:2197-8.

366 Sindrom podhranjenosti, upale i ateroskleroze (MIA) - rizik za bolesti krvnih žila srca i bubrega. U: Simpozij „Bubreg i srce“. Zbornik radova simpozija održanog 14. ožujka 2003. u Zagrebu. Zagreb: Akademija medicinskih znanosti Hrvatske; Hrvatsko društvo za nefrologiju, dijalizu i transplantaciju Hrvatskog liječničkog zbora; 2003.

367 Bubrežna insuficijencija kao posljedica kroničnog zatajenja srca. U: Simpozij „Bubreg i srce“. Zbornik radova simpozija održanog 14. ožujka 2003. u Zagrebu. Zagreb: Akademija medicinskih znanosti Hrvatske; Hrvatsko društvo za nefrologiju, dijalizu i transplantaciju Hrvatskog liječničkog zbora; 2003.

368 Maiese K, Li F, Chong ZZ. Novi putovi istraživanja eritropoetina. JAMA-HR. 2005;2:148-53. Preneseno iz: JAMA. 2005;293:90-5.

369 Anker S. Anaemia and beyond in chronic heart disease. European Society of Cardiology Annual congress 2004. Sophia Antipolis: European Society of Cardiology; 2004. Dostupno na: http://www.escardio.org/initiatives/News/events/esc_congress/Anaemia.htm. Pristup 28. rujna 2007.

370 Kronična opstruktivna plućna bolest. JAMA-HR. 2002;4:261. 371 Lacasse RJ, Leo J. Serotonin and depression: a disconnect between the advertisements

and the scientific literature. PloS Med. 2005;2(12):e392. Dostupno na: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020392. Pristup 24. listopada 2006.

372 DeNoon D. Antidepressants may boost brain growth. New York: Medscape; 2005 Dec 28. Dostupno na: http://www.medscape.com/viewarticle/520680. Pristup 27. listopada 2006.

373 Moss RW. The cancer industry. New York: Equinox Press; 1996. 374 Rath M. Cancer can be beaten. Berlin: Dr. Rath Health Foundation; 2002. Dostupno na:

http://www4.dr-rath-foundation.org/NHC/cancer/lecture/new_york_2002_09_29.htm. Pristup 31. listopada 2006.

375 Thomas CA, Mullis KB, Johnson PE. What causes AIDS? Virusmyth; 1994. Dostupno na: http://www.virusmyth.net/aids/data/kmreason.htm. Pristup 24. listopada 2006.

376 Duesberg P, Rasnick D. The AIDS dilemma: drug diseases blamed on a passenger virus. Genetica. 1998;104:85-132. Dostupno na: http://www.duesberg.com/images/genetica.pdf. Pristup 9. travnja 2008.

377 Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PloS Med. 2005;2(5):e138. Dostupno na: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020138. Pristup 20. listopada 2006.

378 Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflict of interest in biomedical research: a systematic review. JAMA. 2003;289:454-65.

379 Stelfox HT, Chua G, O'Rourke K, et al. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med. 1998;338:101-6.


380 Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282:1453-7.

381 Messori A, Santarlasci B, Trippoli S, et al. “Polypill“ to fight cardiovascular disease. Cost effectiveness of statins for primary prevention of cardiovascular events is questionable. BMJ. 2003;327:808-9.

382 Baker CB, Johnsrud MT, Crismon ML, et al. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry. 2003;183:498-506.

383 Balk EM, Bonis PAL, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA. 2002;287:2973-82.

384 National Institute for Health and Clinical Excellence; British Hypertension Society. Management of hypertension in adults in primary care: pharmacological update. London: Royal College of Physicians; 2006. Dostupno na: http://www.nice.org.uk/guidance/CG34/guidance/pdf/English. Pristup 9. studenoga 2006.

385 Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000;355:2185-8.

386 Torgerson DJ, Bell-Syer SEM. Hormonska nadomjesna terapija i sprječavanje nevertebralnih prijeloma. Meta-analiza randomiziranih istraživanja. JAMA-HR. 2001;4:247-53. Preneseno iz: JAMA. 2001;285:2891-7.

387 Van Walraven C, Hart RG, Singer DE, et al. Usporedba oralnih antikoagulansa i aspirina u nevalvularnoj fibrilaciji atrija. Meta-analiza individualnih bolesnika. JAMA-HR. 2003;2:125-33. Preneseno iz: JAMA. 2002;288:2441-8.

388 Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ. 2001;322:321-6.

389 ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlortalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-75.

390 Steel N. Tresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. BMJ. 2000;320:1446-7.

391 Black HR, Crocitto MT. Number needed to treat: solid science or a path to pernicious rationing? Am J Hypertens. 1998;11:128S-34S.

392 Korn D, Stanski DR, editors. Drug development science. Report of an Invitational Conference organized by The Association of American Medical Colleges, Food and Drug Administration and Center for Drug Development Science at the University of California; 2005 Jan 13-14; Washington DC. The Association of American Medical Colleges; Food and Drug Administration; Center for Drug Development Science at the University of California; 2005.

393 Healy D. Is academic psychiatry for sale? Br J Psychiatry. 2003;182:388-90. 394 Napoli M. How well tested are new cancer drugs? New York: Center for Medical

Consumers; 2002. Dostupno na: http://www.medicalconsumers.org/pages/newsletter_articles.html#how_well_tested. Pristup 16. kolovoza 2006.

395 Sartorius N. Technological development will help people get better health care: true or false? Croat Med J. 2004;45:781-2.

396 Screening for osteoporosis: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:I-59.

397 Sackett DL, Straus SE, Richardson WS, et al. Evidence-based medicine: how to practice


and teach EBM. 2nd ed. New York: Churchill Livingstone; 2000. 398 Marušić M, Kovačić N. Medicina utemeljena na dokazima. U: Marušić M. i sur. Uvod u

znanstveni rad u medicini. 3. izd. Zagreb: Medicinska naklada; 2004. 399 Sackett DL, Rosenberg WM, Gray JAM, et al. Evidence based medicine: what it is and

what it isn´t. BMJ. 1996;312:71-2. 400 Cohen AM, Stavri PZ, Hersh WR. A categorization and analysis of the criticisms of

Evidence-Based Medicine. Int J Med Inform. 2004;73:35-43. 401 Goodman NW. Who will challenge evidence-based medicine? J R Coll Physicians Lond.

1999;33:249-51. 402 Charlton BG, Miles A. The rise and fall of EBM. Q J Med. 1998;91:371-4. 403 Hayward RA, Manning WG, Kaplan SH, et al. Starting insulin therapy in patients with

type 2 diabetes: effectiveness, complications, and resource utilization. JAMA. 1997;278:1663-9.

404 World Health Organization; International Society of Hypertension. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-92.

405 Weber MA. Yet more hypertension guidelines: what do they add? J Hypertens. 2003;21:1977-81.

406 McAlister FA, O'Connor AM, Wells G, et al. When should hypertension be treated? The different perspectives of Canadian family physicians and patients. CMAJ. 2000;163:403-8.

407 Tonelli MR. The limits of evidence-based medicine. Respir Care. 2001;46:1435-40. 408 Couto JS. Evidence-based medicine: a Kuhnian perspective of a transvestite non-theory. J

Eval Clin Pract. 1998;4:267-75. 409 International Diabetes Federation, Clinical Guidelines Task Force. Global guideline for

Type 2 diabetes. Brussels: International Diabetes Federation; 2005. Dostupno na: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Pristup 11. listopada 2006.

410 Erhardt LR. Should all patients with hypertension also receive a statin? Peti hrvatski kongres o aterosklerozi. Liječ Vjesn. 2005;127 Supl 3:24-5.

411 Kronična bolest bubrega i statini. Liječ Vjesn. 2006;128:345-50. 412 Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the

targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-65.

413 Blake GJ, Rifai N, Buring JE, et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993-9.

414 Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281-6.

415 Simons M, Keller P, Dichgans J, et al. Cholesterol and Alzheimer´s disease. Neurology. 2001;57:1089-93.

416 Newman A, Clutterbuck RD, Powles RL, et al. A comparison of the effect ot the 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin, and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma. 1997;24:533-7.

417 Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation. 1996;61:1469-74.

418 Aspirin u primarnoj i sekundarnoj prevenciji kardiovaskularnih bolesti. Liječničke novine. 15. svibnja 2006.

419 Global Initiative for Asthma (GINA). Global strategy for asthma management and


prevention. Updated 2005. Global Initiative for Asthma; 2005. Dostupno na: http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=60. Pristup 31. kolovoza 2006.

420 Novosti u liječenju reumatoidnog artritisa. Vjesnik. 10. listopada 2004. 421 Lipton RB, Stewart WF, Stone AM, et al. Strategija stratificiranog liječenja u odnosu na

strategije stupnjevitog liječenja migrene. Studija onesposobljenosti u strategijama liječenja: randomizirani pokus. JAMA-HR. 2001;2:89-96. Preneseno iz: JAMA. 2000;284:2599-605.

422 Matchar D, McCrory DC, Gray RN. Prema znanstveno utemeljenom zbrinjavanju migrene. JAMA-HR. 2001;2:140-2. Preneseno iz: JAMA. 2000;284:2640-1.

423 Antibiotici u liječenju akutnih egzacerbacija kronične opstruktivne plućne bolesti. Liječničke novine. 15. studenoga 2003.

424 Kendrick M. High blood pressure: it´s a symptom, not a disease, stupid! International Network of Cholesterol Skeptics; 2003 Jan. Dostupno na: http://www.thincs.org/Malcolm.htm#hypertens1. Pristup 26. listopada 2006.

425 Meigs JB, Nathan DM, D'Agostino RB, et al. Fasting and postchallenge glycemia and cardiovascular disease risk. Diabetes Care. 2002;25:1845-50.

426 Miličević Z. Akutni infarkt miokarda i tip 2 šećerne bolesti (HEART 2D studija). Treći hrvatski internistički kongres; 7.-10. listopada 2004.; Opatija. Usmeno izlaganje.

427 Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Arch Intern Med. 1992;152:56-64.

428 Schatz IJ, Masaki K, Yano K, et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet. 2001;358:351-5.

429 Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA. 1994;272:1335-40.

430 Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation. 1992;86:1046-60.

431 Ulmer H, Kelleher C, Diem G, et al. Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality. J Womens Health. 2004;13:41-53.

432 Weverling-Rijnsburger AWE, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350:1119-23.

433 Ravnskov U. The cholesterol myths: exposing the fallacy that saturated fat and cholesterol cause heart disease. Winona Lake: New Trends Publishing; 2000.

434 Hartenbach W. Laž o kolesterolu. Zagreb: Erudita; 2004. 435 Andersson OK, Almgren T, Persson B, et al. Survival in treated hypertension: follow up

study after two decades. BMJ. 1998;317:167-71. 436 O'Brien E, Staessen JA. What is hypertension? Lancet. 1999;354:594. 437 Barbui C, Campomori A, D'Avanzo B, et al. Antidepressant drug use in Italy since the

introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol. 1999;34:152-6.

438 Pyörälä K. A polypill a day keeps the doctor away. U: Ceconi C, editor. ESC Congress Report 2004. Sophia Antipolis: European Society of Cardiology; 2004. Dostupno na: http://www.escardio.org/congresses/esc_congress_2004/Documents/ESC-Congress-Reports-2004.pdf. Pristup 7. lipnja 2007.

439 Tableta protiv debljine i pušenja uskoro na tržištu. Jutarnji list. 1. rujna 2004.


440 Kuehn BM. „Politableta“ bi mogla drastično smanjiti dijabetičke komplikacije. JAMA-HR. 2006;5:319-21. Preneseno iz: JAMA. 2006;296:377-80.

441 American Diabetes Association. Postprandial blood glucose. Consensus statement. Diabetes Care. 2001;24:775-8.

442 American College of Endocrinology. Consensus statement on guidelines for glycemic control. Endocr Pract. 2002;8 Suppl 1:5-11.

443 Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. A prospective study. Circulation. 2003;107:1401-6.

444 Kendrick M. Idiotic thinking in medicine. C-reactive protein. International Network of Cholesterol Skeptics; 2002 Nov. Dostupno na: http://www.thincs.org/Malcolm.htm#CRP. Pristup 29. kolovoza 2006.

445 Schulze MB, Rimm EB, Li T, et al. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004;27:889-94.

446 Soinio M, Marniemi J, Laakso M, et al. Elevated plasma homocystein level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med. 2004;140:94-100.

447 Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. New York: Medscape; 2007 Sep 19. Dostupno na: http://www.medscape.com/viewarticle/561319?src=mp. Pristup 27. rujna 2007.

448 Melzer D, Zimmern R. Genetics and medicalization. BMJ. 2002;324:863-4. 449 Evans JG, Rose G. Hypertension. Br Med Bull. 1971;27:37-42. 450 Pater C. Beyond the evidence of the new hypertension guidelines. Blood pressure

measurement - is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (1). Curr Control Trials Cardiovasc Med. 2005;6:6.

451 Murray S, James MA. What is hypertension? Lancet. 1999;354:593-4. 452 Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood

pressure lowering in hypertensive patients of the HOT Study with different risk prifiles: does a J-shaped curve exist in smokers? J Hypertens. 2003;21:797-804.

453 Krolewski AS, Laffel LMB, Krolewski M, et al. Glycosilated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995;332:1251-5.

454 DCCT Research Group. The absence of glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289-98.

455 Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12,4 years. Diabetes Care. 1999;22:233-40.

456 Mitka M. Smjernice: Nova, još niža, ciljna razina LDL-a. JAMA-HR. 2004;6:431-2. Preneseno iz: JAMA. 2004;292:911-3.

457 Vrhovac B. i sur. Interna medicina. Zagreb: Naprijed; 1991. 458 Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in

Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-20.

459 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.


460 Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.

461 Napoli M. Prehypertension - new medical condition identified. New York: Center for Medical Consumers; 2003. Dostupno na: http://www.medicalconsumers.org/pages/Prehypertension.html. Pristup 4. listopada 2006.

462 Bagatin J. Što nam donose upute WHO/ISH i British Hypertension Society? U: Klinička nefrologija i arterijska hipertenzija - novosti na pragu milenija. Pregled sažetaka i dia-pozitiva tečaja trajnog usavršavanja liječnika održanog 12.-13. svibnja 2000. u Zagrebu. Zagreb: Zavod za nefrologiju i arterijsku hipertenziju Interne klinike Rebro; Društvo za razvitak nefrologije „Prof. dr. Milovan Radonić“; Hrvatsko društvo za hipertenziju; 2000.

463 Brookes L. New definition of hypertension proposed. New York: Medscape; 2005. Dostupno na: http://www.medscape.com/viewarticle/505745. Pristup 23. svibnja 2007.

464 European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabetic Med. 1999;16:716-30.

465 American Diabetes Association. Clinical practice recommendations 2006. Diabetes Care. 2006;29 Suppl 1:S1-85.

466 European Association for the Study of Obesity (EASO), Obesity Management Task Force. Management of obesity in adults: project for European primary care. Int J Obes. 2004;28:S226-31.

467 Alberti KGMM, Zimmet P, Shaw J, et al. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-62.

468 Hrvatsko društvo za osteoporozu. Osteoporoza: smjernice za prevenciju, dijagnostiku i liječenje. Zagreb: Štritof; 1998.

469 Gæde P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93.

470 Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93:1487-94.

471 Chengxuan Q, von Strauss E, Winblad B, et al. Decline in blood pressure over time and risk of dementia. Stroke. 2004;35:1810-15.

472 EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J. 2001;22:554-72.

473 Stergiou GS, Karotsis AK, Symeonidis A, et al. Aggressive blood pressure control in general practice (ABC-GP) study: can the new targets be reached? J Hum Hypertens. 2003;17:767-73.

474 Erceg M, Hrabak-Žerjavić V, Ivičević-Uhernik A. Hrvatska zdravstvena anketa: povišeni krvni tlak. U: Vuletić S, Heim I, Strnad M, et al., ur. Prostorna distribucija populacijskih kardiovaskularnih rizika u Hrvatskoj. Knjiga sažetaka simpozija održanog 2. prosinca 2005. u Zagrebu. Zagreb: Akademija medicinskih znanosti Hrvatske; 2005.

475 Jelaković B. Epidemiologija arterijske hipertenzije u Hrvatskoj: rezultati EH UH studije. U: Vuletić S, Heim I, Strnad M, et al., ur. Prostorna distribucija populacijskih kardiovaskularnih rizika u Hrvatskoj. Knjiga sažetaka simpozija održanog 2. prosinca 2005. u Zagrebu. Zagreb: Akademija medicinskih znanosti Hrvatske; 2005.

476 Jelaković B, Dika Ž, Kos J, et al. Liječenje i kontrola arterijske hipertenzije u Hrvatskoj. BEL-AH istraživanje. Liječ Vjesn. 2006;128:329-33.

477 Gill GV, Woodward A, Pradhan S, et al. Intensified treatment of type 2 diabetes - positive effects on blood pressure, but not glycaemic control. Quart J Med. 2003;96:833-6.


478 Dunn NR, Bough P. Standards of care of diabetic patients in a typical English community. Br J Gen Pract. 1996;46:401-5.

479 Počanić D, Klinar I. Uloga medija u edukaciji bolesnika. Medicus. 2003;12:139-41. 480 Flack JM, Novikov SV, Ferrario CM. Benefits of adherence to antihypertensive drug

therapy. Eur Heart J. 1996;17 Suppl A:16-20. 481 Westin S, Heath I. Thresholds for normal blood pressure and serum cholesterol. BMJ.

2005;330:1461-2. 482 Getz L, Kirkengen AL, Hetlevik I, et al. Ethical dilemmas arising from implementation of

the European Guidelines on cardiovascular disease prevention in clinical practice. A descriptive epidemiological study. Scand J Prim Health Care. 2004;22:202-8.

483 Prevencija kardiovaskularnih incidenata atorvastatinom u hipertoničara s normalnim ili blago povišenim kolesterolom - još jedan putokaz za promjenu stavova. Rezultati ASCOT-LLA studije. HINEKA. 2003;6.

484 Skupina autora DCCT/EDIC-a. Učinci intenzivnog liječenja na mikrovaskularne komplikacije šećerne bolesti tipa 1. JAMA-HR. 2002;4:287-93. Preneseno iz: JAMA. 2002;287:2563-9.

485 Strnad M. Kardiovaskularni čimbenici rizika u hipertenzivnoj populaciji. U: Prvi hrvatski kongres o hipertenziji s međunarodnim sudjelovanjem. Zagreb: Hrvatsko društvo za hipertenziju; 2006.

486 Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA. 2003;289:2363-9.

487 Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44:398-404.

488 Metelko Ž, Pavlić-Renar I, Poljičanin T, et al. The first national diabetes prevalence study in Croatia - unexpectedly high prevalence. Diabetes. 2004;53 Suppl 2:A250.

489 Svjetski dan osteoporoze. Liječničke novine. 15. studenoga 2004. 490 Depresivno 100 milijuna Kineza. Vjesnik. 4. travnja 2005. 491 Abboud L. Treating children for bipolar disorder. Wall Street Journal. 2005 May 25.

Dostupno na: http://www.aifa.it/documenti/rassegna_stampa/RS-25-05-05-WallStreetJ.pdf. Pristup 4. svibnja 2007.

492 Liječenje kroničnog kongestivnog zatajivanja srca. U: Simpozij „Bubreg i srce“. Zbornik radova simpozija održanog 14. ožujka 2003. u Zagrebu. Zagreb: Akademija medicinskih znanosti Hrvatske; Hrvatsko društvo za nefrologiju, dijalizu i transplantaciju Hrvatskog liječničkog zbora; 2003.

493 Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin- receptor blocker. N Engl J Med. 2006;354:1685-97.

494 Prevention of diabetes with troglitazone or pioglitazone (Summary of an oral presentation by Dr Buchanan). U: Summaries of selected highlights of the 1st International Congress on „Prediabetes“ and the Metabolic Syndrome, Berlin, Germany, April 13-16, 2005. Kenes; 2005. Dostupno na: http://www.kenes.com/prediabetes2005/summary_prediabetes_april15.asp. Pristup 19. kolovoza 2007.

495 Yarnall KSH, Pollak KI, Østbye T, et al. Primary care: is there enough time for prevention? Am J Pub Health. 2003;93:635-41.

496 Hippisley-Cox J, Pringle M. General practice workload implications of the national service framework for coronary heart disease: cross sectional survey. BMJ. 2001;323:269-70.

497 Logan A. Small benefits at enormous expense. U: Rapid responses to: Toop L, Richards


D. Preventing cardiovascular disease in primary care. BMJ. 2001;323:246-7. Dostupno na: http://bmj.bmjjournals.com/cgi/eletters/323/7307/246#1593595. Pristup 27. ožujka 2007.

498 Getz L, Sigurdson JA, Hetlevik I. Is opportunistic disease prevention in the consultation ethically justifiable? BMJ. 2003;327:498-500.

499 Sackett D. The arrogance of preventive medicine. CMAJ. 2002;167:363-4. 500 Ohkubo T, Kikuja M, Metoki H, et al. Prognosis of „masked“ hypertension and „white-

coat“ hypertension detected by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol. 2005;46:508-15.

501 Robbins SL. Patologijske osnove bolesti. Zagreb: Školska knjiga; 1979. 502 Wade JP. Rheumatology: 15. Osteoporosis (review). CMAJ. 2001;165:45-50. 503 Premenstrual dysphoric disorder. Madison: Facts for Health. Dostupno na:

http://www.pmdd.factsforhealth.org. Pristup 27. listopada 2006. 504 Wender PH. Attention-deficit hyperactivity disorder in adults. Psychiatr Clin North Am.

1998;21:761-74. 505 Metabolički sindrom u bolesnika s hipertenzijom. Liječ Vjesn. 2006;128:333-6. 506 Morrison C, Woodward M, Leslie W, et al. Effect of socioeconomic group on incidence

of, management of, and survival after myocardial infarction and coronary death: analysis of community coronary event register. BMJ. 1997;314:541-6.

507 Macintyre K, Stewart S, Chalmers J, et al. Relation between socioeconomic deprivation and death from a first myocardial infarction in Scotland: population based analysis. BMJ. 2001;322:1152-3.

508 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23-33.

509 Ramsay S. No closure in sight for the 10/90 health research gap. Lancet. 2001;358:1348. 510 Pecoul B. Access to essential drugs in poor countries. A lost battle? JAMA.

1999;281:361-7. 511 Tuberkuloza u Hrvatskoj. Liječničke novine. 15. rujna 2006. 512 Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly

detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE) study. J Hypertens. 2003;21:1563-74.

513 Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312-8.

514 Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOP-ERATE): a randomized controlled trial. Lancet. 2003;361:117-24.

515 Arai T, Sekizawa S, Ohrui T, et al. ACE inhibitors and protection against pneumonia in elderly patients with stroke. Neurology. 2005;64:573-4.

516 Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-31.

517 EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J. 1997;18:1569-82.

518 Prvi svjetski dan borbe protiv psorijaze. Liječničke novine. 15. studenoga 2004. 519 Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of

a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-4.


520 Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957-63.

521 The Clinical Quality Improvement Network (CQIN) Investigators. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol. 1995;76:570-3.

522 Hoerger TJ, Bala MW, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol. 1998;82:61-5.

523 Pearson TA, Laurora I, Chu H, et al. The Lipid Teatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-67.

524 Rutinske snimke torakalnih organa unaprjeđuju otkrivanje prijeloma kralješaka povezanih s osteoporozom. Liječničke novine. 15. srpnja 2004.

525 Frolkis JP, Zyzanski SJ, Schwartz JM, et al. Physician noncompliance with the 1993 national cholesterol education program (NCEP-ATP II) guidelines. Circulation. 1998;98:851-5.

526 Muratova VN, Islam SS, Demerath EW, et al. Cholesterol screening among children and their parents. Prev Med. 2001;33:1-6.

527 Boulware LE, Daumit GL, Frick KD, et al. An evidence-based review of patient-centered behavioral interventions for hypertension. Am J Prev Med. 2001;21:221-32.

528 Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819-22.

529 Kiortsis DN, Giral P, Bruckert E, et al. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther. 2000;25:445-51.

530 Babyak M, Blumenthal JA, Herman S, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med. 2000;62:633-8.

531 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. Executive summary. Global Initiative for Chronic Obstructive Lung Disease; 2001. Dostupno na: http://goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=1106&archived=1. Pristup 30. kolovoza 2006.

532 Lakatos P, Christiansen C, Marton I, editors. New Europe consensus on osteoporosis 2003. Dostupno na: http://www.iofbonehealth.org/download/osteofound/filemanager/policy_advocacy/pdf/lacrima.pdf. Pristup 9. studenoga 2006.

533 Petrak J. Narav i ustrojstvo sustava medicinskih informacija. U: Marušić M. i sur. Uvod u znanstveni rad u medicini. 3. izd. Zagreb: Medicinska naklada; 2004.

534 Dia-Präsentation von Merck Gesellshaft mbH. zum Thema MICARDIS, MICARDISPLUS - Laufende Studien. Gablitz: Krause & Pachernegg; 2005. Dostupno na: http://www.kup.at/journals/abbildungen/bildsatz/72.html. Pristup 20. listopada 2006.

535 Dr. Matthias Rath - biography. Berlin: Dr. Rath Health Foundation; 2005. Dostupno na: http://www4.dr-rath-foundation.org/THE_FOUNDATION/About_Dr_Matthias_Rath/dr_rath.htm. Pristup 21. prosinca 2006.

536 Dieppe P, Chard J, Tallon D, et al. Funding clinical research. Lancet. 1999;353:1626. 537 International Menopause Society, Executive Committee. Guidelines for hormone


treatment of women in the menopausal transition and beyond. Climacteric. 2004;7:333-7. 538 Brookes L. New evidence of blood pressure-independent effects for agents acting via the

renin- angiotensin system: analyses from The Blood Pressure Lowering Treatment Trialists' Collaboration. New York: Medscape; 2005. Dostupno na: http://www.medscape.com/viewarticle/507293. Pristup 31. siječnja 2007.

539 European Generic Medicines Association. A bitter pill to swallow. Myths and realities of the pharmaceutical industry. Brussels: European Generic Medicines Association; 2003. Dostupno na: http://www.egagenerics.com/doc/ega_myths-reality.pdf. Pristup 16. kolovoza 2006.

540 Generički lijek nije uvijek identičan originalu. Večernji list. 27. listopada 2007. 541 Lefkowitz RJ, Willerson JT. Budućnost kardiovaskularnog istraživanja. JAMA-HR.

2001;3:159-65. Preneseno iz: JAMA. 2001;285:581-7. 542 „Viagra za mozak“ iz snova prelazi u stvarnost. Večernji list. 31. prosinca 2004. 543 Gay Stolberg S. The biotech death of Jesse Gelsinger. New York Times. 1999 Nov 28.

Dostupno na: http://www.uvm.edu/~biology/Classes/012/Jess.pdf. Pristup 3. veljače 2007.

544 Sisti D. Gene therapy and the case of Jesse Gelsinger. Philadelphia: University of Pennsylvania, Center for Bioethics, 2004. Dostupno na: http://www.bioethics.upenn.edu/highschool/Briefs/?t=1&a=6. Pristup 20. listopada 2006.

545 Rosenberg SA. Secrecy in medical research. N Engl J Med. 1996;334:392-4. 546 Od pacijenta pacijentu. Bilten Hrvatske udruge za promicanje prava pacijenata. Srpanj

2004. 547 Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA.

2000;283:2701-11. 548 Marušić M, Katavić V, Hren D. Znanstvenoistraživačka čestitost. U: Marušić M. i sur.

Uvod u znanstveni rad u medicini. 3. izd. Zagreb: Medicinska naklada; 2004. 549 Hayward RSA, Wilson MC, Tunis SR, et al. More informative abstacts of articles

describing clinical practice guidelines. Ann Int Med. 1993;118:731-7. 550 The AGREE Collaboration. Development and validation of an international appraisal

instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 2003;12:18-23.

551 Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab za bolesnike sa srednje teškom i teškom psorijazom u obliku plakova. JAMA-HR. 2004;2:103-11. Preneseno iz: JAMA. 2003;290:3073-80.

552 Zinberg DS. Editorial. Science. 1996;273:411. 553 McNeil C. Who invented the VLP cervical cancer vaccines? J Natl Cancer Inst.

2006;98:433. 554 Goozner M. The $800 million pill: the truth behind the cost of new drugs. Berkeley:

University of California Press; 2004. 555 Mitka M. Ponovno promišljanje liječenja bolesnika sa šećernom i kardiovaskularnom

bolesti. JAMA-HR. 2002;4:258-9. Preneseno iz: JAMA. 2002;287:2488-91. 556 Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-

CRO study). Eur J Cardiovasc Prevention Rehab. 2006;13:646-54. 557 Sekundarna prevencija ishemijske bolesti srca u Općoj bolnici Bjelovar: usporedba

rezultata LIBS I- V studije. Peti kongres Hrvatskog kardiološkog društva. Poster. Liječ Vjesn. 2004;126 Supl 1:83.

558 Stavovi hrvatskih liječnika o prevenciji hiperlipidemija i kardiovaskularnih bolesti. Peti hrvatski kongres o aterosklerozi. Liječ Vjesn. 2005;127 Supl 3:23-4.

559 Gagnon M-A, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical


promotion expenditures in the United States. Plos Med. 2008;5(1):e1. Dostupno na: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050001. Pristup 5. travnja 2008.

560 Pfizer. New York: Pfizer. Dostupno na: http://www.pfizer.com. Pristup 1. rujna 2006. 561 Vrček V. Prostitucija znanosti. Glas Koncila. 12. ožujka 2006. 562 Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT. London: International Centre for

Circulatory Health; National Heart & Lung Institute; Imperial College London. Dostupno na: http://www.ascotstudy.co.uk. Pristup 12. rujna 2006.

563 Shaughnessy AF, Slawson DC. Pharmaceutical representatives. BMJ. 1996;312:1494. 564 Hrvatska liječnička komora. Pravilnik o sadržaju, rokovima i postupku trajne medicinske

izobrazbe i provjere stručnosti liječnika. Zagreb: Hrvatska liječnička komora; 2006. Dostupno na: http://www.hlk.hr/default.asp?ru=120&gl=200504130000017&sid=&jezik=1. Pristup 25. listopada 2006.

565 Cirkulacija bez zapreka! Liječničke novine. 15. travnja 2004. 566 Moynihan R. Claims by charity exaggerate dangers of osteoporosis. BMJ. 2003;327:358. 567 Tuffs A. Only 6% of drug advertising material is supported by evidence. BMJ.

2004;328:485. 568 Villanueva P, Peiro S, Librero J, et al. Accuracy of pharmaceutical advertisements in

medical journals. Lancet. 2003;361:27-32. 569 Wilkes MS, Doblin BH, Shaipiro MF. Pharmaceutical advertisements in leading medical

journals: experts' assessments. Ann Intern Med. 1992;116:912-9. 570 Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician

prescribing patterns. There´s no such thing as a free lunch. Chest. 1992;102:270-3. 571 Komesaroff PA, Kerridge IH. Ethical issuses concerning the relationships between

medical practitioners and the pharmaceutical industry. MJA. 2002;176:118-21. 572 Wasana A. Physicians and the pharmaceutical industry. JAMA. 2000;283:373-80. 573 Lexchin J. Interactions between physicians and pharmaceutical industry: what does the

literature say? CMAJ. 1993;149:1401-7. 574 Watkins C, Moore L, Harvey I, et al. Characteristics of general practitioners who

frequently see drug industry representatives: national cross sectional study. BMJ. 2003;326:1178-9.

575 Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med. 1988;26:1183-9.

576 Lurie N, Rich EC, Simpson DE, et al. Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. J Gen Intern Med. 1990;5:240-3.

577 Cleary JD. Impact of pharmaceutical sales representatives on physician antibiotic prescribing. J Pharm Technol. 1992;8:27-9.

578 Bower AD, Burkett GL. Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. J Fam Pract. 1987;24:612-6.

579 Caudill TS, Johnson MS, Rich EC, et al. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med. 1996;5:201-6.

580 Bota B, Slugan I. Uloga farmaceutske industrije u radu podružnica i stručnih društava Hrvatskog

liječničkog zbora. U: Bakran I, Ivanišević G, ur. Suradnja liječnika i farmaceutske industrije u trajnoj izobrazbi. Knjiga izlaganja na III proljetnom bioetičkom simpoziju Hrvatskoga

liječničkog zbora održanom u Zagrebu 6. lipnja 2003. Zagreb: Hrvatski liječnički zbor; 2003.


581 Banerjee P, Banerjee T, Khand A, et al. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol. 2002;39:138-41.

582 Kmietowicz Z. Consumer organisations criticise influence of drug companies. BMJ. 2004;329:937.

583 Glaxo sued for “drug claim fraud“. BBC News; 2004 Jun 2. Dostupno na: http://news.bbc.co.uk/2/hi/business/3771429.stm. Pristup 9. studenoga 2006.

584 Izaberi zdravlje. Hrvatski radio. 18. siječnja 2005. 585 Relman AS. Defending professional independence. JAMA. 2003;289:2418-20. 586 Uloga novijih antihipertenziva i statina u prevenciji moždanog udara. Zagreb: PLIVAmed

net; 21. veljače 2005. Dostupno na: http://www.PLIVAMED.net/?section=home&cat=t&show=18id=8613. Pristup 2. veljače 2007.

587 Liberati A, Magrini N. Information from drug companies and opinion leaders. BMJ. 2003;326:1156-7.

588 Fisher M, Schaebitz W. Pregled liječenja akutnog moždanog udara. Prošlost, sadašnjost i budućnost. JAMA-HR. 2001;3:203-13. Preneseno iz: Arch Intern Med. 2000;160:3196-206.

589 Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemografic factors. JAMA. 1992;267:64-9.

590 Bugiardini R, Merz CNB. Angina s „normalnim“ koronarnim arterijama. Promjena pristupa. JAMA-HR. 2005;3:219-26. Preneseno iz: JAMA. 2005;293:477-84.

591 Mitka M. Biomarkeri za koronarnu bolest: prognostička vrijednost ili samo dodatna pretraga. JAMA-HR. 2005;2:95-6. Preneseno iz: JAMA. 2004;292:2824-5.

592 Statini u primarnoj i sekundarnoj prevenciji koronarne bolesti. Medicus. 2003;1:85-90. 593 Hormonsko liječenje u postmenopauzi. Liječničke novine. 15. listopada 2002. 594 Još jedan pogled na ALLHAT. HINEKA. 2003;6. 595 Kako procijeniti pravi odnos cijene liječenja i postignute dobrobiti? JAMA-HR.

2004;4:332-4. 596 Should HPV vaccines be mandatory for all adolescents? Lancet. 2006;368:1212. 597 Fox KM. Management of coronary artery disease: implications of the EUROPA trial. Br J

Cardiol. 2004;11:195-204. 598 Hrvatski konsenzus o hormonskom nadomjesnom liječenju u klimakteriju i

postmenopauzi. Poreč, 27.- 29. ožujka 1998. 599 Hormoni nisu lijek za aterosklerozu. Vjesnik. 18. svibnja 2003. 600 Protuaterosklerotski učinci antihipertenziva. Liječ Vjesn. 2006;128:341-5. 601 Brady AJB. ASCOT, and the evolution of guidelines for hypertension. U: Prvi hrvatski

kongres o hipertenziji s međunarodnim sudjelovanjem. Zagreb: Hrvatsko društvo za hipertenziju; 2006.

602 Regulacija postprandijalne glikemije u liječenju dijabetesa tipa 2 i ateroskleroze. Peti hrvatski kongres o aterosklerozi. Liječ Vjesn. 2005;127 Supl 3:34-5.

603 Fentanilski naljepak može biti opasan. Liječničke novine. 15. veljače 2006. 604 Opet i još o transdermalnom fentanilu. Liječničke novine. 15. svibnja 2006. 605 Fentanilski naljepak ipak nije opasan! Liječničke novine. 15. travnja 2006. 606 GSK Piramida. Metabolički sindrom. 4. hrvatski internistički kongres. Opatija, 5.- 8.

listopada 2006. (CD-ROM). GlaxoSmithKline; 2006. 607 Čala S. Diuretici u liječenju arterijske hipertenzije. U: Prvi hrvatski kongres o hipertenziji

s međunarodnim sudjelovanjem. Zagreb: Hrvatsko društvo za hipertenziju; 2006.


608 Liječničke pogreške u kardiologiji. Liječničke novine. 15. ožujka 2005. 609 Najčešće pogreške u primjeni lijekova. Rasprava oko okruglog stola. Drugi hrvatski

internistički kongres. Liječ Vjesn. 2002;124 Supl 3:25-31. 610 2. Hrvatski kongres o osteoporozi. Liječničke novine. 15. travnja 2003. 611 Prvi hrvatski simpozij o beskrvnom liječenju. Liječničke novine. 15. rujna 2004. 612 Moynihan R. Who pays for pizza? Redefining the relationships between doctors and drug

companies. 1: Entanglement. BMJ. 2003;326:1189-92. 613 Prescription drug marketing. Center for Policy Alternatives; 2006. Dostupno na:

http://www.stateaction.org/issues/issue.cfm/issue/PrescriptionDrugMarketing.xmlm. Pristup 1. prosinca 2006.

614 Liječenje boli u reumatskih bolesnika naljepkom (flasterom). Liječničke novine. 15. veljače 2003.

615 Eritropoetin u liječenju hematoloških i onkoloških bolesnika. Liječničke novine. 15. svibnja 2006.

616 Liječenje depresije moklobemidom. Liječničke novine. 15. travnja 2003. 617 Bero LA, Galbraith A, Rennie D. The publication of sponsored symposiums in medical

journals. N Engl J Med. 1992;327:1135-40. 618 Moynihan R. Drug company sponsorship of education could be replaced at a fraction of

its cost. BMJ. 2003;326:1163. 619 European Union of Medical Specialists. Criteria for international accreditation of CME

(reviewed July 1999). Brussels: European Union of Medical Specialists; 1999. Dostupno na: http://www.uems.net/uploadedfiles/46.pdf. Pristup 17. veljače 2005.

620 Treći hrvatski internistički kongres. Liječničke novine. 15. studenoga 2004. 621 Hrvatski simpozij, a na - Malti? Liječničke novine. 15. lipnja 2004. 622 Relman AS. Separating continuing medical education from pharmaceutical marketing.

JAMA. 2001;285:2009-12. 623 Hrvatski liječnici isplaćivani preko računa u Austriji. Slobodna Dalmacija. 11. studenoga

2004. 624 Coyle SL, for the Ethics and Human Rights Committee, American College of Physicians

- American Society of Internal Medicine. Physician - industry relations. Part 1: Individual physicians. Ann Intern Med. 2002;136:396-402.

625 Ekspertiza. Otvorena televizija. 9. siječnja 2005. 626 Institute for Clinical Systems Improvement. Depression, major, in adults in primary care.

Priority aims and suggested measures for health care systems. Bloomington: Institute for Clinical Systems Improvement; 2004. Dostupno na: http://www.icsi.org/knowledge/detail.asp?catID=29&itemID=180. Pristup 4. prosinca 2006.

627 Smjernice CPME-a za jačanje uloge pacijenata u postupku liječenja. Liječničke novine. 15. listopada 2004.

628 Prozac budi stare neurone. 24 sata. 29. travnja 2008. 629 Slučaj Pegasys - hoće li Državno odvjetništvo otkriti krivca? Liječničke novine. 15.

srpnja 2003. 630 Liječnici protiv ministra Ljubičića. Jutarnji list. 24., 25. i 26. prosinca 2005. 631 Ferriman A. Selling drugs to consumers. BMJ. 1999;319:1208. 632 Mintzes B. Direct to consumer advertising is medicalising normal human experience.

BMJ. 2002;324:908-11. 633 Moynihan R, Bero L, Ross-Degnan D, et al. Coverage by the news media of the benefits

and risks of medications. N Engl J Med. 2000;342:1645-50.


634 Moynihan R, Sweet M. Medicine, the media and monetary interests: the need for transparency and professionalism. MJA. 2000;173:631-4.

635 Neki nisu ni svjesni da imaju dijabetes. Vjesnik. 10. listopada 2004. 636 U svijetu više od 300 000 astmatičara. Liječničke novine. 15. lipnja 2004. 637 Od astme u Hrvatskoj boluje više od šest posto stanovništva. Vjesnik. 23. siječnja 2005. 638 Repaglinid u liječenju šećerne bolesti. Vita. Ožujak 2002. 639 U Hrvatskoj 44 posto ljudi s povišenim krvnim tlakom. Večernji list. 8. prosinca 2004. 640 152 milijuna osoba s problemom erekcije. Zagreb News. 19. srpnja 2006. 641 Na pomolu cjepivo i lijek protiv dijabetesa. Jutarnji list. 14. prosinca 2004. 642 Za dijabetes intenzivan tretman. Večernji list. 12. siječnja 2006. 643 Živjeti s depresijom. Pliva. Dodatak Večernjeg lista. 3. prosinca 2005. 644 Izaberi zdravlje. Hrvatski radio. 19. listopada 2004. 645 Izaberi zdravlje. Hrvatski radio. 10. svibnja 2005. 646 Ekspertiza. Otvorena televizija. 6. veljače 2005. 647 Ekspertiza. Otvorena televizija. 17. listopada 2004. 648 Ekspertiza. Otvorena televizija. 10. travnja 2005. 649 Ekspertiza. Otvorena televizija. 16. siječnja 2005. 650 Ekspertiza. Otvorena televizija. 6. travnja 2008. 651 Latinica. Hrvatska televizija. 13. veljače 2006. 652 Sanja. RTL. 18. listopada 2004. 653 Otvoreno. Hrvatska televizija. 11. listopada 2005. 654 Podnevni dnevnik. Hrvatska televizija. 6. ožujka 2005. 655 Dnevnik. Hrvatska televizija. 3. prosinca 2005. 656 Dnevnik. Hrvatska televizija. 19. ožujka 2005. 657 ZADI - Zagrebački dijabetičar. Bilten Zagrebačkog dijabetičkog društva. Srpanj 2005. 658 Diabetes. Časopis Hrvatskog saveza dijabetičkih udruga. Svibanj 2007. 659 Putovnica za život. Edukacijski program tvrtke Novartis za bolesnike, u suradnji s

Hrvatskim kardiološkim društvom. Zagreb: Novartis; 2006. 660 Healthy blood sugar targets. Geocities; 2004. Dostupno na:

http://www.geocities.com/jenny_the_bean/bloodsugartargets.htm. Pristup 18. kolovoza 2006.

661 Burton B, Rowell A. Unhealthy spin. BMJ. 2003;326:1205-7. 662 Hrvatsko društvo za osteoporozu. Zagreb: Hrvatsko društvo za osteoporozu. Dostupno

na: http://www.osteoporoza.hr. Pristup 20. listopada 2004. 663 Izaberi zdravlje. Hrvatski radio. 25. siječnja 2005. 664 Više nade za oboljele. Slobodna Dalmacija. 24. siječnja 2005. 665 Glivec od danas na recept i oboljelima od GIST-a. Večernji list. 18. kolovoza 2004. 666 Odbijanjem dijalize prijeti 2600 bolesnika. Večernji list. 29. travnja 2005. 667 Health Action International Europe. Does the European Patients´ Forum represent patient

or industry interests? Amsterdam: Health Action International Europe; 2005. Dostupno na: http://www.haiweb.org/docs2005/EPF%20paper%20final.doc. Pristup 18. kolovoza 2006.

668 International Osteoporosis Foundation. Nyon: International Osteoporosis Foundation. Dostupno na: http://www.osteofound.org. Pristup 14. rujna 2006.

669 Brennan TA. Buying editorials. N Engl J Med. 1994;331:673-5. 670 Larkin M. Whose article is it anyway? Lancet. 1999;354:136. 671 Boseley S. Scandal of scientists who take money for papers ghostwritten by drug

companies. Guardian. 2002 Feb 7. Dostupno na:


http://www.guardian.co.uk/uk/2002/feb/07/research.health1. Pristup 30. svibnja 2008. 672 Vrček V. Avastin - novi farmaceutski poraz? Glas Koncila. 15. kolovoza 2006. 673 Dan migrene. Liječničke novine. 15. travnja 2004. 674 Ljubas J. Svjetski dan srca u Zagrebu. Kardio list. 2006;1:23. 675 Svjetski dan astme. JAMA-HR. 2005;2:133. 676 Izaberi zdravlje. Hrvatski radio. 30. svibnja 2006. 677 Uklanjanje boli u toku antineoplastičkog liječenja. Liječničke novine. 15. veljače 2002. 678 The European Cervical Cancer Prevention Week 2008. Lyon: European Cervical Cancer

Association; 2008. Dostupno na: http://www.ecca.info/webECCA/en/page.jsp?currentBlocId=4&nodeId=313&reader=9. Pristup 28. siječnja 2008.

679 Javnozdravstvena kampanja „Budi Zdrav(k)a“ Hrvatske lige protiv raka. Zagreb: Hrvatska liga protiv raka; 2007. Dostupno na: http://www.zdravka.hlpr.hr/index.php?option=com_content&task=view&id=38&Itemid=43. Pristup 7. veljače 2008.

680 Plaču li samo siromašna djeca? Vjesnik. 12. veljače 2005. 681 Europa i Osijek protiv boli. Liječničke novine. 15. srpnja 2003. 682 Hrvatska kupuje cjepivo protiv virusa pričje gripe. Večernji list. 31. listopada 2006. 683 Svaka je pacijentica priča za sebe. Vjesnik. 18. svibnja 2003. 684 I muškarac može imati iste probleme kao žena. Vjesnik. 18. svibnja 2003. 685 Testosteron u injekciji za muškarce iznad pedesete. Večernji list. 17. studenoga 2006. 686 Moynihan R. Alosetron: a case study in regulatory capture, or a victory for patients´

rights? BMJ. 2002;325:592-5. 687 BMJ rapid responses to: Grundy SM. Should women be offered cholesterol lowering

drugs to prevent cardiovascular disease? Yes. BMJ. 2007;334:982-983. Dostupno na: http://www.bmj.com/cgi/eletters/334/7601/982. Pristup 24. studenoga 2007.

688 Napoli M, Norsigian J, Brenner B, et al. Letter to FDA commissioner McClellan opposing use of surrogate endpoints for approval of cancer prevention drugs. New York: Center for Medical Consumers; 2003. Dostupno na: http://www.medicalconsumers.org/pages/Letter%20To%20FDA-- Approval%20of%20Cancer%20Prevention%20Drugs.html. Pristup 12. svibnja 2005.

689 Abraham J. The pharmaceutical industry as a political player. Lancet. 2002;360:1498-502.

690 Gottlieb S. Company played down drug´s risk, report says. BMJ. 2001;322:696. 691 Levin AA. Science under attack by the Bush administration. New York: Center for

Medical Consumers; 2002. Dostupno na: http://www.medicalconsumers.org/pages/ScienceUnderAttackByBushAdministration.html. Pristup 12. svibnja 2005.

692 Abraham J. Making regulation responsive to commercial interests: streamlining drug industry watchdogs. BMJ. 2002;325:1164-9.

693 Povjerenstvo predložilo Upravnom vijeću HZZO-a proširenje liste s 22 nova lijeka. Večernji list. 29. siječnja 2005.

694 „Lantus“ na recept samo za mlađe od 18 godina. Vjesnik. 5. svibnja 2005. 695 Kako smanjiti visoku potrošnju lijekova u Hrvatskoj? Farmaceutski glasnik. 2004;60:98-

106. 696 Lijekovi boje novca. Globus. 11. srpnja 2003. 697 Štednja na antilipemicima nije štednja. Liječničke novine. 15. ožujka 2002. 698 Izaberi zdravlje. Hrvatski radio. 5. listopada 2004.


699 Nova lista lijekova i posebni fond za rijetke bolesti. Liječničke novine. 15. ožujka 2002. 700 Od Gauchera boluju i Hrvati. Liječničke novine. 15. listopada 2002. 701 Otvoreno. Hrvatska televizija. 11. ožujka 2008. 702 Moulton B. The case against Directive 2001/20/EC: The “Save European Research“

campaign. Health Watch; 2004 Apr. Dostupno na: http://www.healthwatch-uk.org/newsletterarchive/nlett53.html. Pristup 27. studenoga 2006.

703 Lijekovi liječe sidu bolje od lažnog moraliziranja. Večernji list. 17. srpnja 2004. 704 Bogati i poznati dospijevaju na vrh popisa osoba za transplantaciju. Vjesnik. 3. prosinca

2004. 705 Zakon o obveznom zdravstvenom osiguranju. NN, 85/2006. 26. srpnja 2006. 706 Zakon o izmjenama i dopunama Zakona o zdravstvenoj zaštiti. NN, 85/2006. 26. srpnja

2006. 707 Gužve na farmaceutskoj sceni. Jutarnji list. 16. studenoga 2004. 708 Regulatory threats. Dorking: Alliance for Natural Health; 2006. Dostupno na:

http://www.alliance-natural-health.org/index.cfm?action=content.eu.Default. Pristup 30. studenoga 2006.

709 Zakon o lijekovima i medicinskim proizvodima. NN, 121/2003. 29. srpnja 2003. 710 Brown S. The Medicare Index. New York Times. 2004 Jan 28. Dostupno na:

http://www.medicalconsumers.org/pages/TheNewMedicareLegislationinContext.html. Pristup 18. kolovoza 2006.

711 Outlaw the „business with disease“: The Chemnitz Programme. Berlin: Dr. Rath Health Foundation; 1997. Dostupno na: http://www4.dr-rath-foundation.org/PHARMACEUTICAL_BUSINESS/The_Chemnitz_Programme/index.htm. Pristup 28. studenoga 2006.

712 Lilienthal SM. The coming of the psychotherapeutic state? Washington Dispatch. 2004 Oct 20. Dostupno na: http://www.washingtondispatch.com/article_10364.shtml. Pristup 28. studenoga 2006.

713 Grube laži o „tajnoj večeri“. Vjesnik. 8. rujna 2006. 714 Cijene lijekova uskoro pet posto niže. Vjesnik. 5. studenoga 2004. 715 Žužul u New York poslao čovjeka pod istragom. Večernji list. 10. studenoga 2004. 716 Novim testovima dodatno smanjiti mogućnost zaraze HIV-om. Liječničke novine. 15.

rujna 2004. 717 Mundy A. Dispensing with the truth: the victims, the drug companies, and the dramatic

story behind the battle over Fen-Phen. New York: St. Martin´s Press; 2002. 718 Deoul K. Cancer cover-up: an indictment of Big Medicine and their suppression of the

cesium cancer therapy. West Caldwell: Cassandra Books; 2001. Dostupno na: http://www.cassandrabooks.com/coverup/footnotes.htm. Pristup 6. prosinca 2006.

719 Pfizer issues prosecutors a manual to defend drug. Star Ledger. 2004 Aug 5. Dostupno na: http://www.ahrp.org/infomail/04/08/05/php. Pristup 25. studenoga 2006.

720 Imamo Nacionalni program za zaštitu od dijabetesa! Diabetes. Svibanj 2007. 721 European Society of Cardiology. Sophia Antipolis: European Society of Cardiology.

Dostupno na: http://www.escardio.org. Pristup 27. veljače 2007. 722 Muney AM. Evidence-based medicine needs to be promoted more vigorously. Managed

Care Magazine. 2002 Feb. Dostupno na: http://www.managedcaremag.com/archives/0202/0202.muney.html. Pristup 31. svibnja 2008.

723 Organizirano liječenje boli u Hrvatskoj od 1979. do 2001. Liječničke novine. 15. veljače 2002.


724 SZO i liječenje boli. Liječničke novine. 15. travnja 2002. 725 European Cervical Cancer Association. Lyon: European Cervical Cancer Association.

Dostupno na: http://www.ecca.info/webECCA/en/. Pristup 17. veljače 2008. 726 Peticija „STOP raku vrata maternice u Europi“. HČJZ. 2008;13. Dostupno na:

http://www.hcjz.hr/clanak.php?id=13595. Pristup 15. siječnja 2008. 727 Europski tjedan prevencije raka vrata maternice, 20.-26.01.2008. Cybermed; 17. siječnja

2008. Dostupno na: http://ww.cybermed.hr/index.php/pbl/portal_za_pacijente/vijesti/europski_tjedan_prevencije_raka_vrata_maternice_20_26_01_2008. Pristup 18. veljače 2008.

728 Više od 38000 potpisa na peticiji „Prekrižimo rak vrata maternice“. Zagreb: PLIVAzdravlje; 23. siječnja 2008. Dostupno na: http://plivazdravlje.hr/?section=home&id=19192&show=1. Pristup 7. veljače 2008.

729 Complaint against genocide and other crimes against humanity commited in connection with the pharmaceutical „business with disease“ and the recent war against Iraq. Berlin: Dr. Rath Health Foundation; 2003. Dostupno na: http://www4.dr-rath-foundation.org/The_Hague/complaint/complaint00.htm. Pristup 2. siječnja 2007.

730 Testiranje lijeka: unosni biznis koji spašava živote. Nacional. 3. lipnja 2003. 731 Rezultati poslovanja PLIVE za 2003. godinu. Zagreb: Pliva; 2004. Dostupno na:

http://www.pliva.ba/ba/aktualnosti1-2004.htm. Pristup 16. kolovoza 2006. 732 Lijekovi: na dobitku svi osim pacijenata. Večernji list. 3. kolovoza 2004. 733 Pliva izgubila 350 milijuna $ u SAD-u. Jutarnji list. 20. svibnja 2005. 734 Napoli M. Conference addresses corporate influences on medical research. New York:

Center for Medical Consumers; 2003. Dostupno na: http://www.medicalconsumers.org/pages/integrity_in_science.html. Pristup 17. kolovoza 2006.

735 Controversies: asthma drug controversy climaxes. Epidemiology Monitor. 1990 Mar. Dostupno na: http://www.epimonitor.net/EpiWitWisdom/controversies1.htm. Pristup 6. prosinca 2006.

736 Kowalczyk L. Drug companies' secret reports outrage doctors. Boston Globe. 2003 May 25. Dostupno na: http://www.antidepressantsfacts.com/2003-05-25-Boston-Globe.htm. Pristup 30. studenoga 2006.

737 Povodom optužbi za korupciju u zdravstvu. Liječničke novine. 15. svibnja 2006. 738 Država razbija korupciju farmaceuta i liječnika. Novi list. 23. svibnja 2005. 739 Dvojici liječnika plaćali 5000 kuna mjesečno za promidžbu. Večernji list. 12. studenoga

2004. 740 Liječnici na platnoj listi Pfizera. Globus. 19. studenoga 2004. 741 AIDS drug priced at $20,000. CNN Business; 2003 Feb 24. Dostupno na:

http://www.cnn.com/2003/BUSINESS/02/24/roche/index.html. Pristup 9. kolovoza 2006. 742 Herxheimer A. Relationships between the pharmaceutical industry and patients'

organizations. BMJ. 2003;326:1208-10. 743 Visoke ocjene za HSDU. Diabetes. Svibanj 2007. 744 Sweet M. Sponsored journalism award shocks Australian media. BMJ. 2001;323:1258. 745 Medika otkazala put u Tunis za ravnatelje bolnica. Jutarnji list. 4. veljače 2005. 746 Lijekovi, liječnici i večere. Jutarnji list. 26. studenoga 2007. 747 Hodges B. Interactions with the pharmaceutical industry: experiences and attitudes of

psychiatry residents, interns and clerks. CMAJ. 1995;153:553-9. 748 Liječnik s Rebra na putu čak 281 dan. Večernji list. 12. srpnja 2006. 749 Brett AS, Burr W, Maloo J. Are gifts from pharmaceutical companies ethically


problematic? Arch Intern Med. 2003;163:2213-8. 750 Dvadeset ljekarnika na „safari kongresu“ u Južnoj Africi. Večernji list. 18. studenoga

2004. 751 Stav kliničkog farmakologa o trajnoj liječničkoj izobrazbi. U: Bakran I, Ivanišević G, ur.

Suradnja liječnika i farmaceutske industrije u trajnoj izobrazbi. Knjiga izlaganja na III proljetnom bioetičkom simpoziju Hrvatskoga liječničkog zbora održanom u Zagrebu 6. lipnja 2003. Zagreb: Hrvatski liječnički zbor; 2003.

752 Elliot C. Pharma buys a conscience. American Prospect. 2001 Sep 24. Dostupno na: http://www.prospect.org/print/V12/17/elliott-c.html. Pristup 23. kolovoza 2006.

753 Hassner Sharav V. Conflicts of interest in clinical trials. Fourteenth Tri-service Clinical Investigation Symposium; 2002 May 5-7; San Antonio. New York: Alliance for Human Research Protection; 2002. Dostupno na: http://www.ahrp.org/testimonypresentations/armymeddept.php. Pristup 23. kolovoza 2006.

754 Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest. JAMA. 2006;295:429-33.

755 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). ATP III Update 2004: financial disclosure. Bethesda: National Heart, Lung, and Blood Institute; 2004. Dostupno na: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04_disclose.htm. Pristup 22. kolovoza 2006.

756 Choundry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002;287:612-7.

757 Vrček V. Varaju li psihijatri pacijente? Glas Koncila. 15. kolovoza 2004. 758 Iz rada Izvršnog odbora Hrvatske liječničke komore. Liječničke novine. 15. svibnja 2006. 759 Boseley S. Bitter pill. Guardian. 2001 May 7. Dostupno na:

http://www.guardian.co.uk/Archive/Article/0,4273,4181987,00.html. Pristup 10. kolovoza 2006.

760 Thompson J, Baird P, Downie J. Report of the Committee of inquiry on the case involving dr. Nancy Olivieri, the Hospital of Sick Children, the University of Toronto, and Apotex Inc. Ottawa: Canadian Association of University Teachers; 2001. Dostupno na: http://www.caut.ca/en/issues/academicfreedom/OlivieriInquiryOverview.pdf. Pristup 11. kolovoza 2006.

761 Moynihan R. Should drug companies be allowed to sponsor Cochrane reviews? CMAJ. 2003;169:1201.

762 Borovečki A, Oreskovic S, ten Have H. Ethics and the structures of health care in the European countries in transition: hospital ethics committees in Croatia. BMJ. 2005;331:227-9.

763 Vrček V. Medicinski časopisi - produžena ruka industrije. Glas Koncila. 30. listopada 2005.

764 Japsen B. Ex-editor blasts AMA interference. Chicago Tribune. 1999 Feb 17. Dostupno na: http://www.noflouride.com/ama_jama.htm. Pristup 9. kolovoza 2006.

765 Čulig J. Lista esencijalnih lijekova Svjetske zdravstvene organizacije - usporedba s osnovnom listom lijekova Hrvatskog zavoda za zdravstveno osiguranje. U: Udruga poslodavaca u zdravstvu. Lista lijekova Hrvatskog zavoda za zdravstveno osiguranje. Zagreb: Udruga poslodavaca u zdravstvu; studeni 2006.

766 Čulig J. Lijekovi. HČJZ. 2007;10. Dostupno na: http://www.hcjz.hr/clanak.php?id=13424. Pristup 4. lipnja 2008.

767 Cijene lijekova moraju pasti i do 30 posto. Liječničke novine. 15. srpnja 2004.


768 Unatoč prijedlogu povjerenstva, bolnice ipak bez novih lijekova. Večernji list. 30. srpnja 2004.

769 Među najpropisivanijim genericima HZZO najviše troši na Lipex. Liječničke novine. 15. lipnja 2004.

770 Udruga poslodavaca u zdravstvu. Lista lijekova Hrvatskog zavoda za zdravstveno osiguranje. Zagreb: Udruga poslodavaca u zdravstvu; studeni 2006.

771 Lovell-Smith D. Perfect blood pressure - naturally. Auckland: Penguin Books; 2002. 772 Alexander CN, Schneider RH, Staggers F, et al. Trial for stress reduction for

hypertension in older African Americans. II. Sex and risk subgroup analysis. Hypertension. 1996;28:228-37.

773 Castillo-Richmond A, Schneider RH, Alexander CN, et al. Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans. Stroke. 2000;31:568-73.

774 Zamarra JW, Schneider RH, Besseghini I, et al. Usefulness of the transcendental meditation program in the treatment of patients with coronary artery disease. Am J Cardiol. 1996;77:867-70.

775 Herron RE, Schneider RH, Mandarino JV, et al. Cost-effective hypertension management: comparison of drug therapies with an alternative program. Am J Manag Care. 1996;2:427-37.

776 Herron RE, Hills SL, Mandarino JV, et al. Reducing medical costs: the impact of transcendental meditation on government payments to physicians in Quebec. Am J Health Promot. 1996;10:208-16.

777 Vožeh S. Is the increasing use of evidence-based pharmacotherapy causing the renaissance of complementary medicine? Br J Clin Pharmacol. 2003;56:292-6.

778 Knittel L. A new medical model. Yoga Journal. 2003 Jan/Feb. Dostupno na: http://www.yogajournal.com/health/844_1.cfm. Pristup 3. veljače 2005.

779 Coulter ID, Willis EM. The rise and rise of complementary and alternative medicine: a sociological perspective. Med J Aust. 2004;180:587-9.

780 Orthomolecular medicine. Wikipedia. Dostupno na: http://en.wikipedia.org/wiki/Orthomolecular_medicine. Pristup 24. travnja 2008.

781 World Health Organization. World health report 1997. Geneva: World Health Organization; 1997. Dostupno na: http://www.who.int/whr/1997/en/whr97_en.pdf. Pristup 7. kolovoza 2006.

782 Preventivno budimo zdravi. Vjesnik. 29. studenoga 2004. 783 Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and

regional burden of disease. Lancet. 2002;360:1347-60. 784 Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years´

observational study on male British doctors. BMJ. 1994;309:901-11. 785 Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mortality after

myocardial infarction. Meta-analysis of cohort studies. Arch Intern Med. 2000;160:939-44.

786 Božićević I, Gilmore A, Oreskovic S. The tobacco epidemic in South-East Europe; consequences and policy responses. Washington DC: World Bank; 2004. Dostupno na: http://www.1.worldbank.org/tobacco/pdf/Bozicevic-Consequences%20of-whole.pdf. Pristup 24. lipnja 2006.

787 Orešković S. Škola narodnog zdravlja: kuća Štamparova bitka. Liječ Vjesn. 2002;124 Supl 2:1-4.

788 U.S. Department of Health and Human Services. Physical activity and health. Report of the Surgeon General. Atlanta: Centers for Disease Control and Prevention; 1996. Dostupno na: http://www.cdc.gov/nccdphp/sgr/sgr.htm. Pristup 12. prosinca 2006.


789 Morris JN. Exercise in the prevention of coronary heart disease: today´s best buy in public health. Med Sci Sports Exercise. 1994;26:807-14.

790 Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on sodium and blood pressure. Hypertension. 2000;35:858-63.

791 Cutler JA, Follmann D, Allender PS. Randomised trials od sodium reduction: an overview. Am J Clin Nutr. 1997;65 Suppl 2:643S-51S.

792 Hooper L, Bartlett C, Davey Smith G, et al. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ. 2002;325:628-32.

793 Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA. 1982;248:1465-77.

794 Hooper L, Summerbell CD, Higgins JPT, et al. Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ. 2001;322:757-63.

795 Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med. 2003;348:2074-81.

796 Yancy WS, Olsen MK, Guyton JR, et al. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia. Ann Intern Med. 2004;140:769-77.

797 Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004;140:778-85.

798 Halton TL, Willet WC, Liu S, et al. Low-carbohydrate-diet score and the risk of coronary heart disease in women. N Engl J Med. 2006;355:1991-2002.

799 Moore HJ, Summerbell CD, Hooper L, et al. Dietary advice for treatment of type 2 diabetes mellitus in adults. Cochrane Database of Systematic Reviews; 2004. Dostupno na: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004097/frame.html. Pristup 19. siječnja 2007.

800 Dansinger ML, Gleason JA, Griffith JL, et al. Usporedba Atkinsove, Ornishove, “Weight Watchers“ i Zona dijete s obzirom na smanjenje tjelesne težine i smanjenje rizika od srčanih bolesti.

JAMA-HR. 2005;2:104-14. Preneseno iz: JAMA. 2005;293:43-53. 801 Upornost u propagiranju mjera protiv kroničnih nezaraznih bolesti. Liječničke novine. 15.

listopada 2004. 802 Law MR, Morris JK. By how much does fruit and vegetable consumption reduce the risk

of ischaemic heart disease? Eur J Clin Nutr. 1998;52:549-56. 803 Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary

sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3-10.

804 Jenkins DJA, Kendall CWC, Marchie A, et al. Učinci dijete obogaćene sastojcima koji snižavaju kolesterol u odnosu na lovastatin na serumske lipide i C-reaktivni protein. JAMA-HR. 2003;6:453-61. Preneseno iz: JAMA. 2003;290:502-10.

805 Rudan I, Vadla D, Strnad M, et al. Mediteranski način prehrane i učestalost zloćudnih tumora probavnog sustava na hrvatskim otocima. Liječ Vjesn. 2003;125:60-7.

806 Hu FB, Willett WC. Optimalna dijeta za sprječavanje koronarne bolesti. JAMA-HR. 2003;2:137-46. Preneseno iz: JAMA. 2002;288:2569-78.

807 Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50.

808 Finnish Diabetes Association. Development programme for the prevention and care of diabetes in Finland 2000-2010. Tampere: Finnish Diabetes Association; 2001. Dostupno


na: http://www.diabetes.fi/english/programme/programme/index.html. Pristup 8. kolovoza 2006.

809 Puska P. Successful prevention of non-communicable diseases: 25 year experiences with North Karelia Project in Finland. Geneva: World Health Organization; 2003. Dostupno na: http://www.who.int/hpr/NPH/docs/successful_prevention.pdf. Pristup 7. kolovoza 2006.

810 Cummings SR, Stein MJ, Hansen B, et al. Smoking counseling and preventive medicine. A survey of internists in private practices and a health maintenance organization. Arch Intern Med. 1989;149:345-9.

811 McPherson K. Public health does not need to be led by doctors. BMJ. 2001;322:1593-4. 812 World Health Organization. World health report 2002. Geneva: World Health

Organization; 2002. Dostupno na: http://www.who.int/whr/2002/en/whr02_en.pdf. Pristup 5. siječnja 2007.

813 Ewing R, Schmid T, Killingsworth R, et al. Relationship between urban sprawl and physical activity, obesitiy and morbidity. Am J Health Promot. 2003;18:47-57.

814 Raphael D. Social justice is good for our hearts: why societal factors - not lifestyles - are major causes of heart disease in Canada and elsewhere. Toronto: CJS Foundation for Research and Education; 2002. Dostupno na: http://www.cwhn.ca/resources/heart_health/justice2.pdf. Pristup 15. prosinca 2006.

815 Marmot MG, Smith GD, Stansfeld S, et al. Health inequalities among British civil servants: the Whitehall II study. Lancet. 1991;337:1387-93.

816 Lynch JW, Kaplan GA, Cohen RD, et al. Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality and acute myocardial infarction? Am J Epidemiol. 1996;144:934-42.

817 Wamala SP, Mittleman MA, Schenck-Gustafsson K, et al. Potential explanations for the educational gradient in coronary heart disease: a population-based case-control study of Swedish women. Am J Public Health. 1999;89:315-21.

818 Lawlor DA, Davey Smith G, Ebrahim S. Association between childhood socioeconomic status and coronary heart disease risk among postmenopausal women: findings from the British women's heart and health study. Am J Public Health. 2004;94:1386-92.

819 Ebrahim S, Montaner D, Lawlor DA. Clustering of risk factors and social class in childhood and adulthood in British women's heart and health study: cross sectional analysis. BMJ. 2004;328:861-4.

820 Power C, Graham H, Due P, et al. The contribution of childhood and adult socioeconomic position to adult obesity and smoking behaviour: an international comparison. Int J Epidemiol. 2005;34:335-44.

821 Levitt NS, Lambert EV, Woods D, et al. Impaired glucose tolerance and elevated blood pressure in low birth weight, nonobese, young South African adults: early programming of cortisol axis. J Clin Endocrinol Metab. 2000;85:4611-8.

822 Carlsson S, Persson PG, Alvarsson M, et al. Low birth weight, family history of diabetes, and glucose intolerance in Swedish middle-aged men. Diabetes Care. 1999;22:1043-7.

823 Barker DJP, Winter PD, Osmond C, et al. Weight in infancy and death from ischaemic heart disease. Lancet. 1989;334:577-80.

824 Bosma H, Peter R, Siegrist J, et al. Two alternative job stress models and the risk of coronary heart disease. Am J Public Health. 1998;88:68-74.

825 Knutsson A, Akerstedt T, Jonsson BG, et al. Increased risk of ischaemic heart disease in shift workers. Lancet. 1986;2:89-92.

826 Sacker A, Bartley JM, Frith D, et al. The relationship between job strain and coronary heart disease: evidence from an English sample of the working male population. Psychol


Med. 2001;31:279-90. 827 Orth-Gomer K, Wamala SP, Horsten M, et al. Marital stress worsens prognosis in women

with coronary heart disease: The Stockholm Female Coronary Risk Study. JAMA. 2000;284:3008-14.

828 Kawachi I, Kennedy BP. Socioeconomic determinants of health: health and social cohesion: why care about income inequality? BMJ. 1997;314:1037-40.

829 Kawachi I, Colditz GA, Ascherio A, et al. A prospective study of social networks in relation to total mortality and cardiovascular disease in men in the USA. J Epidemiol Community Health. 1996;50:245-51.

830 Vogt TM, Mullooly JP, Ernst D, et al. Social networks as predictors of ischaemic heart disease, cancer, stroke and hypertension: incidence, survival and mortality. J Clin Epidemiol. 1992;45:659-66.

831 Hemingway H, Marmot M. Psychosocial factors in the aetiology and prognosis of coronary heart disease: systematic review of prospective cohort studies. BMJ. 1999;318:1460-7.

832 Berkman LF, Leo-Summers L, Horwitz RI. Emotional support and survival after myocardial infarction. A prospective, population-based study of the elderly. Ann Intern Med. 1992;117:1003-9.

833 Krumholz HM, Butler J, Miller J, et al. Prognostic importance of emotional support for elderly patients hospitalized with heart failure. Circulation. 1998;97:958-64.

834 Williams RB, Barefoot JC, Califf RM, et al. Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. JAMA. 1992;267:520-4.

835 Mauksch LB, Tucker SM, Katon WJ, et al. Mental illness, functional impairment, and patient preferences for collaborative care in an uninsured, primary care population. J Fam Pract. 2001;50:41-7.

836 Williams RB, Schneiderman N. Resolved: Psychosocial interventions can improve clinical outcomes in organic disease (Pro). Psychosom Med. 2002;64:552-7.

837 Miller TQ, Smith TW, Turner CW, et al. A meta-analytic review of research on hostility and physical health. Psychol Bull. 1996;119:322-48.

838 Rosengren A, Hawken S, Ôunpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:953-62.

839 Stansfeld S, Marmot M, editors. Stress and the heart: psychosocial pathways to coronary heart disease. London: BMJ Books; 2002.

840 Macleod J, Smith GD, Heslop P, et al. Psychological stress and cardiovascular disease: empirical demonstration of bias in a prospective observational study of Scottish men. BMJ. 2002;324:1247-51.

841 Pušenje i siromaštvo - zatvoreni krug. Liječničke novine. 15. lipnja 2004. 842 Kumari M, Head J, Marmot M. Prospective study of social and other risk factors for

incidence of type 2 diabetes in the Whitehall II study. Arch Intern Med. 2004;164:1873-80.

843 Colhoun HM, Rubens MB, Underwood SR, et al. Cross sectional study of differences in coronary artery calcification by socioeconomic status. BMJ. 2000;321:1262-3.

844 Lantz PM, House JS, Lepkowski JM, et al. Socioeconomic factors, health behaviors, and mortality. JAMA. 1998;279:1703-8.

845 Hofrichter R, editor. Health and social justice: politics, ideology, and inequity in the distribution of disease. San Francisco: Jossey-Bass; 2003. Dostupno na: http://media.wiley.com/product_data/excerpt/35/07879673/0787967335.pdf. Pristup 20.


prosinca 2006. 846 Wilkinson RG. Socioeconomic determinants of health. Health inequalities: relative or

absolute material standards? BMJ. 1997;314:591-5. 847 Kennedy BP, Kawachi I, Prothrow-Stith D. Income distribution and mortality: cross-

sectional ecological study of the Robin Hood Index in United States. BMJ. 1996;312:1004-7.

848 Kawachi I, Kennedy B, Wilkinson RG, editors. The Society and Population Health Reader: Income inequality and health. New York: New Press; 1999.

849 Hertzman C. Health and human society. American Scientist. 2001;89:538-45. 850 Ross NA, Wolfson MC, Dunn JR, et al. Relation between income inequality and

mortality in Canada and in the United States: cross sectional assessment using census data and vital statistics. BMJ. 2000;320:898-902.

851 Poverty raises heart attack risk. BBC News; 2001 May 11. Dostupno na: http://news.bbc.co.uk/1/hi/health/1323362.stm. Pristup 19. siječnja 2007.

852 Zaidi S. Hrvatska: Ocjena životnog standarda. World Bank; 2007. Dostupno na: http://siteresources.worldbank.org/INTCROATIA/Resources/CroatiaLSAcroatian.pdf. Pristup 8. studenoga 2007.

853 Svaki šesti Hrvat ispod granice siromaštva. Vjesnik. 21. studenoga 2004. 854 Brajša: Mali čovjek nije nikad tako loše živio kao danas. Vjesnik. 21. studenoga 2004. 855 4200 Zagrepčana u redu za hranu. Vjesnik. 21. studenoga 2004. 856 Modeli razvoja dobrovoljnih zdravstvenih osiguranja kod nas i u svijetu. Liječničke

novine. 15. studenoga 2004. 857 World Health Organization. World health report 1995. Geneva: World Health

Organization; 1995. Dostupno na: http://www.who.int/whr/1995/en/whr95_en.pdf. Pristup 7. kolovoza 2006.

858 World Health Organization. World health report 2003. Geneva: World Health Organization; 2003. Dostupno na: http://www.who.int/whr/2003/en/whr03_en.pdf. Pristup 8. kolovoza 2006.

859 75 godina ŠNZ „Andrija Štampar“ priča je o uspjehu. Liječničke novine. 15. listopada 2002.

860 Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med. 1996;156:745-52.

861 Jones DA, West RR. Psychological rehabilitation after myocardial infarction: multicentre randomised controlled trial. BMJ. 1996;313:1517-21.

862 Frasure-Smith N, Lesperance F, Prince RH, et al. Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. Lancet. 1997;350:473-9.

863 Šogorić S, Lang S, Šoić Z, et al. Potpora promišljanjima o preobrazbi sustava zdravstva u Republici Hrvatskoj. Liječ Vjesn. 2002;124 Supl 2:13-7.

864 Šogorić S. Zašto EPOHA ZDRAVLJA. Epoha zdravlja. Travanj 2005. 865 Hrvatska mreža zdravih gradova. Zagreb: Hrvatska mreža zdravih gradova, Škola

narodnog zdravlja „Andrija Štampar“ Medicinskog fakulteta Sveučilišta u Zagrebu. Dostupno na: http://www.zdravi-gradovi.com.hr/hrv/index.asp. Pristup 22. prosinca 2006.

866 Svaka majka i dijete su važni. Liječničke novine. 15. travnja 2005. 867 Shlomo YB, Kuh D. A life course approach to chronic disease epidemiology: conceptual

models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol. 2002;31:285-93.

868 World Health Organization. Ottawa Charter for Health Promotion. Geneva: World Health Organization; 1986. Dostupno na:


http://www.who.int/healthpromotion/conferences/previous/ottawa/en/. Pristup 20. prosinca 2006.

869 Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3:343-53.

870 Raphael D. Poor choice or no choice? Even more evidence links low income with disease, so why keep blaming lifestyle choices like fries? Toronto Star. 2002 Oct 11. Dostupno na: http://mailman1.u.washington.edu/pipermail/pophealth/2002-October/000379.html. Pristup 8. kolovoza 2006.

871 Jakšić Ž. Savjesni kompromis s realnošću bez kompromisa savjesti. Liječ Vjesn. 2002;124 Supl 2:5-12.

872 Od pozvanih na pregled čak 39 posto bolesno. Večernji list. 22. listopada 2004. 873 World Health Organization. World health report 1998. Geneva: World Health

Organization; 1998. Dostupno na: http://www.who.int/whr/1998/en/whr98_en.pdf. Pristup 8. kolovoza 2006.

874 Berkow R, Cohen J. The cri$i$ in academic medicine. Croat Med J. 2005;46:4-9. 875 Horton R. The dawn of McScience. New York Review of Books. 2004 Mar 11. Dostupno

na: http://www.pahealthsystems.com/message8107.html. Pristup 17. veljače 2007. 876 Štifanić M. Novi tehnološko-medicinski kompleks. U: Plenković J. i sur. Tehnologija i

razvoj društva. Rijeka: Građevinski fakultet Sveučilišta u Rijeci; 1998. 877 Matulić T. Autonomija trajne liječničke izobrazbe u kontekstu sukoba interesa u

medicinskoj praksi. U: Bakran I, Ivanišević G, ur. Suradnja liječnika i farmaceutske industrije u trajnoj izobrazbi.

Knjiga izlaganja na III proljetnom bioetičkom simpoziju Hrvatskoga liječničkog zbora održanom u Zagrebu 6. lipnja 2003. Zagreb: Hrvatski liječnički zbor; 2003.

878 Matić D. Ratovi znanosti: pogled unatrag. Zagreb: Jesenski i Turk; 2001. 879 Treba nam povjerenje u znanost, a ne znanje o njoj. Vjesnik. 3. studenoga 2002. 880 World Health Organization. World health report 2000. Geneva: World Health

Organization; 2000. Chapter 1. Why do health systems matter? Dostupno na: http://www.who.int/whr/2000/en/whr00_en.pdf. Pristup 5. siječnja 2007.

881 World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles

for medical research involving human subjects. Ferney-Voltaire: World Medical Association; 2004. Dostupno na: http://www.wma.net/e/policy/b3.htm. Pristup 3. studenoga 2006.

882 Moher D, Jadad AR, Nichol G, et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials. 1995;16:62-73.

883 Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377-84.

884 Marušić A. Pisanje znanstvenoga članka. U: Marušić M. i sur. Uvod u znanstveni rad u medicini. 3. izd. Zagreb: Medicinska naklada; 2004.

885 Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999;354:1896-900.

886 Petrovečki M, Scheetz MD. Croatian Medical Journal introduces culture, control, and the study of research integrity. Croat Med J. 2001;42:7-13.

887 Office of Research Integrity. Rockville: Office of Research Integrity. Dostupno na: http://ori.dhhs.gov. Pristup 5. siječnja 2007.

888 Sastanak Vancouverske skupine u Hrvatskoj - velik uspjeh hrvatske medicinske znanosti. Liječničke novine. 15. srpnja 2004.


889 Registracija kliničkih pokusa. Izjava Međunarodnog odbora urednika medicinskih časopisa. JAMA-HR. 2005;1:69-70. Preneseno iz: JAMA. 2004;292:1363-4.

890 Hrvatska liječnička komora. Kodeks medicinske etike i deontologije. Zagreb: Hrvatska liječnička komora; 2006.

891 Group seeks limits on drug-financed doctors. New York: Alliance for Human Research Protection; 2004. Dostupno na: http://www.ahrp.org/infomail/04/09/28.php. Pristup 1. travnja 2006.

892 „Blic“ razgovor s prodekanicom za poslijediplomsku nastavu MEF-a u Zagrebu prof. dr. Smiljom Kalenić. Liječničke novine. 15. ožujka 2005.

893 Clinical drug trials “distorted“. BBC News; 2004 Sep 9. Dostupno na: http://news.bbc.co.uk/hi/health/3640488.stm. Pristup 16. kolovoza 2006.

894 World Medical Association. World Medical Association International Code of Medical Ethics. Ferney-Voltaire: World Medical Association; 2006. Dostupno na:

http://www.wma.net/e/policy/c8.htm. Pristup 18. kolovoza 2006. 895 American Medical Association. Code of Medical Ethics: current opinions with

annotations 2002- 2003. Chicago: American Medical Association; 2003. 896 Comite Permanent Des Medecins Europeens; The European Federation of

Pharmaceutical Industries and Associations. Joint Declaration of CPME and EFPIA on the Cooperation between the Medical Profession and the Pharmaceutical Industry. Comite Permanent Des Medecins Europeens; The European Federation of Pharmaceutical Industries and Associations; 2005. Dostupno na: http://213.49.133.32:591/database/CPME-EFPIA%20Joint%20Declaration.pdf. Pristup 5. siječnja 2007.

897 Prijedlozi zaključaka Hrvatskog liječničkog zbora o trajnoj liječničkoj izobrazbi. U: Bakran I, Ivanišević G, ur. Suradnja liječnika i farmaceutske industrije u trajnoj izobrazbi. Knjiga izlaganja na III proljetnom bioetičkom simpoziju Hrvatskoga liječničkog zbora održanom u Zagrebu 6. lipnja 2003. Zagreb: Hrvatski liječnički zbor; 2003.

898 Association of American Medical Colleges, Task Force on Financial Conflicts of Interest in Clinical Research. Protecting subjects, preserving trust, promoting progress - policy and guidelines for the oversight of individual financial interests in human subjects research. Washington DC: Association of American Medical Colleges; 2001. Dostupno na: http://www.aamc.org/members/coitf/firstreport.pdf. Pristup 25. svibnja 2006.

899 World Medical Association. The World Medical Association Statement Concerning the Relationship between Physicians and Commercial Enterprises. Ferney Voltaire: World Medical Association; 2004. Dostupno na: http://www.wma.net/e/policy/r2.htm. Pristup 23. kolovoza 2006.

900 Korn D. Conflict of interest in biomedical research. JAMA. 2000;284:2234-7. 901 Coyle SL, for the Ethics and Human Rights Committee, American College of Physicians

- American Society of Internal Medicine. Physician - industry relations. Part 2. Organizational Issues. Ann Intern Med. 2002;136:403-6.

902 Association of American Medical Colleges, Task Force on Financial Conflicts of Interest in Clinical Research. Protecting subjects, preserving trust, promoting progress II: principles and recommendations for oversight of institution´s financial interests in human subjects research. Washington DC: Association of American Medical Colleges; 2002. Dostupno na: http://www.aamc.org/members/coitf/2002coireport.pdf. Pristup 17. travnja 2006.

903 Stav Hrvatskoga liječničkog zbora prema dokumentu Svjetske liječničke udruge o odnosu liječnika i trgovačkih društava. U: Bakran I, Ivanišević G, ur. Suradnja liječnika i


farmaceutske industrije u trajnoj izobrazbi. Knjiga izlaganja na III proljetnom bioetičkom simpoziju Hrvatskoga liječničkog zbora održanom u Zagrebu 6. lipnja 2003. Zagreb: Hrvatski liječnički zbor; 2003.

904 Sukob interesa u medicini i znanosti. Liječničke novine. 15. lipnja 2002. 905 Gunjača M, Blažević E, Schönwald D. Uloga strane farmaceutske industrije u trajnoj

izobrazbi liječnika. U: Bakran I, Ivanišević G, ur. Suradnja liječnika i farmaceutske industrije u trajnoj izobrazbi. Knjiga izlaganja na III proljetnom bioetičkom simpoziju Hrvatskoga liječničkog zbora održanom u Zagrebu 6. lipnja 2003. Zagreb: Hrvatski liječnički zbor; 2003.

906 Dobrodošla podrška farmaceutske industrije, ali u drugačijem obliku. Liječničke novine. 15. prosinca 2004.

907 Matulić T. Etika kao etiketa tehnike i ekonomije - medicinska znanost u ozračju instrumentalne racionalnosti. U: Etika u medicinskoj znanosti. Zbornik radova sa simpozija „Etika u medicinskoj znanosti“ održanog u Zagrebu, 27. listopada 2007. Zagreb: Hrvatsko katoličko liječničko društvo; 2007.

908 Bosman FT. Academic medicine: dream or nightmare? Croat Med J. 2004;45:371-4. 909 Eckel RH. Dijetni pristup debljini. JAMA-HR. 2005;2:155-6. Preneseno iz: JAMA.

2005;293:96-7. 910 About ICSPP. New York: International Center for the Study of Psychiatry and

Psychology. Dostupno na: http://www.icspp.org/index.php?option=com_content&task=view&id=90&Itemid=55. Pristup 22. kolovoza 2006.

911 Svaki deseti lijek krivotvoren! Vjesnik. 4. rujna 2006. 912 Štifanić M. Tehnologija i medicina. U: Plenković J. Društvo i tehnologija. Rijeka:

Građevinski fakultet Sveučilišta u Rijeci; 1994. 913 Berkow R. Medical education: creating physicians or medical technicians? Croat Med J.

2002;43:45-9. 914 Heath I. Who needs health care - the well or the sick? BMJ. 2005;330:954-6. 915 Fowler PBS. Some answers, more controversy from UKPDS. Lancet. 1998;352:832-3. 916 Little PJ. The PROSPER trial. Lancet. 2003;361:428. 917 Umirovljenica podigla kredit za lijek koji je na listi HZZO-a. Index.hr; 11. svibnja 2005.

Dostupno na: http://www.index.hr/clanak.aspx?id=264744. Pristup 11. svibnja 2005. 918 Odbijaju platiti lijek o kojemu mi ovisi život. Večernji list. 4. listopada 2004. 919 Moynihan R, Smith R. Too much medicine? BMJ. 2002;324:859-60. 920 Vitas B. Neracionalnost caruje (Quo vadit medicina?). Liječ Vjesn. 2006;128:6-7. 921 Štulhofer M. Racionalizacija medicine - globalni problem. Liječničke novine. 15.

studenoga 2005. 922 Clark J, Smith R. BMJ Publishing Group to launch an international campaign to promote

academic medicine. BMJ. 2003;327:1001-2. 923 Fatović-Ferenčić S. Free the dinosaurs into butterfly gardens: in a search for changing the

profile of the academic professional. Croat Med J. 2004;45:375-7. 924 Jones A. Mutualism and interdependence: a Gaian critique of science and society. 4.

Lošinjski dani bioetike; 13.-15. lipnja 2005.; Mali Lošinj. Usmeno izlaganje. 925 Simić Z. Predgovor. U: Ilič I. Medicinska Nemezis. Beograd: Vuk Karadžić; 1975. 926 Čović A. Pluralizam i pluriperspektivizam. Fil. istraž. 2006;26:7-11. 927 Čović A. Etika i bioetika. Zagreb: Pergamena; 2004. 928 Vrček V. Interakcija suvremene znanosti i javnosti. Nova prisutnost. 2004;2:103-18. 929 Vrček V. Nasilje znanosti. Glas Koncila. 13. ožujka 2005.


930 Matulić T. Vodič kroz bioetiku III. Medicinsko prevrednovanje etičkih granica. Zagreb: Glas Koncila; 2006.

931 Matulić T. Vodič kroz bioetiku II. Život u ljudskim rukama. Zagreb: Glas Koncila; 2006. 932 European Union of Medical Specialists. Autonomy of medical specialist practice.

Declaration. Brussels: European Union of Medical Specialists; 1994. Dostupno na: http://www.uems.net/uploadedfiles/181.pdf#search=%22uems%20declaration%20autonomy%20physicians%22. Pristup 18. rujna 2006.

933 Rušinović Sunara Đ, Proso M. Some legally questions of protecting patients rights. Zbornik radova Pravnog fakulteta u Splitu. 2005;3:381-90.

934 Jurić H. Zdravlje i vrijednosti. HČJZ. 2006;6. Dostupno na: http://www.hcjz.hr/clanak.php?id=12800&. Pristup 12. siječnja 2007.

935 Tomašević L. U hodu s vremenom. Tomislavgrad: Naša ognjišta; 2004. 936 Craig RP, Middleton CL, O'Connell LJ. Etički komiteti. Zagreb: Pergamena; 1998. 937 Smith R. In search of “non-disease“. BMJ. 2002;324:883-5. 938 Tomašević L. Smrt i njezino (ne)dostojanstvo. U: Valjan V, urednik. Integrativna

bioetika i izazovi suvremene civilizacije. Zbornik radova Prvog međunarodnog bioetičkog simpozija u Bosni i Hercegovini (Sarajevo, 31. III - 1. IV 2006.). Sarajevo: Bioetičko društvo u BiH; 2007.

939 Hebert K. Life expectancy in Great Britain rises - but later years are still spent in poor health. BMJ. 2004;329:250.

940 Barber N. What constitutes good prescribing. BMJ. 1995;310:923-5. 941 Vuletić S. Naturalističko raspitivanje - zanemarena istraživačka paradigma u javnom

zdravstvu. Liječ Vjesn. 2002;124 Supl 2:45-8. 942 Majka protiv zakona: Neće mi dijete trovati cjepivom. Večernji list. 3. travnja 2008. 943 Hrvatska udruga za promicanje prava pacijenata, Radna grupa za izradu prijedloga

Zakona o pravima, obvezama i odgovornostima pacijenata. Prijedlog Zakona o pravima, obvezama i odgovornostima pacijenata. Split: Hrvatska udruga za promicanje prava pacijenata; 2002. Dostupno na: http://www.pravapacijenata.hr/zakon.html. Pristup 18. rujna 2006.

944 Rušinović-Sunara Đ. Partnerstvo u zdravstvenom sustavu ili čovjek kao centar svih interesa. Liječničke novine. 15. svibnja 2004.

945 Center for Medical Consumers. New York: Center for Medical Consumers. Dostupno na: http://www.medicalconsumers.org/. Pristup 19. ožujka 2007.

946 Healthy Skepticism. International Network of Cholesterol Skeptics. Dostupno na: http://www.healthyskepticism.org/. Pristup 3. travnja 2007.

947 Health Action International. Amsterdam: Health Action International. Dostupno na: http://www.haiweb.org/. Pristup 22. studenoga 2006.

948 Alliance for Human Research Protection. New York: Alliance for Human Research Protection. Dostupno na: http://www.ahrp.org/cms/content/view/18/87/. Pristup 8. svibnja 2007.

949 Lončarek K. Industrija bolesti. Feral Tribune. 7. svibnja 2004.